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To my family
 Abstract 
Understanding the solution conformation and dynamics of molecules with 
biological relevance, as well as the impact of their conformation stabilizing weak 
interactions, is for example important for drug design. Macrocycles have attractive 
pharmaceutical properties, and are of special interest as drug leads for targets with 
large, flat and featureless binding sites like protein-protein interfaces. As they are 
usually flexible and adopt a variety of solution geometries, the description of their 
ensembles is of high value. Most macrocyclic drugs are peptides or macrolides. 
Peptides, and in particular β-hairpin peptides, are suitable model systems for 
studying weak interactions. Due to their resemblance to proteins, studying peptides 
by solution state experiments provides knowledge gained in a biologically relevant 
environment. In this thesis, nuclear magnetic resonance (NMR) spectroscopy has 
been used for investigation of the solution ensembles of various macrocycles. 
Using a cyclic β-hairpin model system and NMR analysis of molecular flexibility in 
solution (NAMFIS), a single interstrand hydrogen bond was shown to provide 
significant stabilization of the folded conformation. In addition, it was shown that a 
chlorine-centered halogen bond stabilizes the β-hairpin to a comparable extent. 
Further, the solution ensembles of four cyclic β-hairpin inhibitors of the 
MDM2/p53 protein-protein interaction were described, and a higher 
conformational flexibility was found to correlate with an increased inhibitory 
activity. In contrast, for cyclic azapeptide inhibitors of the cluster of differentiation 
36 (CD36) receptor, higher flexibility correlated to decreased inhibitory activity. An 
increased population of one of the conformational families in solution was found 
to be beneficial for the CD36 inhibitory activity. Lastly, roxithromycin, a macrolide 
antibacterial agent, was described to convert from a more open conformation in 
polar media to a more closed and less flexible conformation in non-polar media. 
This thesis demonstrates that macrocycles are applicable as model systems for the 
study of weak interaction forces, which have a large influence on their 
conformational behavior. Furthermore, the obtained results show that the 
conformational stability of macrocycles vastly influences their bioactivity. 
 
Keywords: Macrocycles, cyclic peptides, NMR, solution conformational analysis, 
NAMFIS, β-hairpin, weak interactions, halogen bonding, protein-protein 
interaction, bioactive conformation, macrolides, cell permeable conformation.  
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 1. General introduction 
Life is all about molecular motion. The conformational behavior and the 
interactions of complex molecules in a three-dimensional space run nearly every 
aspect of biology. If we can describe the dynamics and the interactions of 
biomolecules and their ligands we gain valuable information that can be used, for 
example, in the design of drugs. The conformational change of biological molecules 
in solution is a result of forming and breaking a number of weak interactions such 
as hydrogen bonds, hydrophobic interactions, and π-stacking. Since these 
interactions are weak, biological systems are flexible. These cooperatively acting 
weak forces and the conformational dynamics generated are to a large extent 
responsible for the function of biological systems. The same is true when a 
ligand/drug molecule binds to a biological target macromolecule. In order for the 
ligand to bind with high affinity, these precise interactions have to be generated and 
the ligand has to be able to adopt the 3D conformations required to fit into the 
binding pocket of the macromolecule. In drug design, drug candidates are 
optimized with respect to this bioactive conformation and to the corresponding 
interactions to the target macromolecule, which is typically a protein. Obtaining 
information of the biologically active conformation and the interactions involved is 
therefore of high importance. 
 
There are several methods available for collecting information about the structure, 
conformation and interactions of molecules with biochemical relevance, including 
X-ray diffraction, Raman spectroscopy, infrared (IR) spectroscopy, molecular 
mechanics (MM) and molecular dynamics (MD) calculations, optical rotation and 
circular dichroism (CD) spectroscopy, single particle cryo-electron microscopy 
(cryo-EM), and nuclear magnetic resonance (NMR) spectroscopy. The two that 
have found the most widespread use are X-ray diffraction and NMR spectroscopy. 
X-ray diffraction provides crystal structures with detailed atomic-level information 
of the 3D structure of molecules in the solid state. This technique is without doubt 
the most powerful tool to obtain information about the 3D geometry. However, 
since measured in the solid state, the generated structure is static and not dynamic 
as it would be in solution. On the other hand, NMR spectroscopy can be measured 
in solution and thereby gives information on the dynamics and conformational 
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 behavior of the studied molecule, as well as on their interactions, in a context that 
better resembles a biological environment. Both X-ray diffraction and NMR 
spectroscopy have been awarded with several Nobel prizes.1,2 
  
 
2. Macrocycles 
Classical drug development has focused on small molecule drugs with properties 
within the Lipinski rule of five,3 in other words with molecular weight ≤ 500 Da, 
cLogP ≤ 5, hydrogen bond donors (HBD) ≤ 5, and hydrogen bond acceptors 
(HBA) ≤ 10. Lipinski’s rules can be viewed as guidelines for oral bioavailability, and 
they have been extended to include polar surface area (PSA) ≤ 140 Å2 and number 
of rotatable bonds ≤ 10.4,5 There are also larger protein-based biological 
therapeutics, typically with molecular weight > 5000 Da.6 These biological drugs 
have been successfully used to modulate targets with exceptional specificity and 
potency. However, they violate Lipinski’s rules resulting in poor cell permeability 
and low bioavailability, and they are typically administrated intravenously.6,7 Since a 
large part of the human proteome has been classified as difficult to modulate using 
small molecules,8 a lot of effort is presently put into bridging the gap of small 
molecules and biologics.6,9-11 One strategy for this is to use macrocycles, that is 
cyclic compounds comprising of 12 atoms or more.12 Macrocycles usually have 
molecular weights >500 Da and offer an alternative to small molecule drug 
candidates, providing high specificity, affinity and chemical diversity but still have a 
better chance of cell permeability than the biologics.7,11,13 They are often referred to 
as beyond rule of five (bRo5) ligands since they have properties outside Lipinski’s 
rule of five,10,14 and they are of special interest as drug leads for non-conventional 
targets with large, flat and featureless binding sites like protein-protein interactions 
(PPIs).10,12,13 As most macrocyclic drugs are cyclic peptides or macrolides,13 
macrocycles are commonly classified as peptidic or non-peptidic natural products, 
synthetic peptides or synthetic macrocycles.15 Cyclic peptides have attained 
increased attention for their attractive pharmaceutical properties as compared to 
their linear analogues.7, 16 Since peptides commonly require constrains to retain their 
3D structure in water and usually have low bioavailability, peptide cyclization is 
frequently used to increase their folding. Cyclization leads to minimized metabolic 
degradation in the gut, blood and tissues as a result of removing the cleavable N- 
and C-termini. In addition, the generated conformations often have decreased 
exposure of polar atoms to the surroundings, which might increase oral 
bioavailability.7 Likewise, cyclization is also commonly utilized in order to lock the 
peptide in the bioactive conformation, and thereby increase the bioactivity.17 Even 
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 though there are issues such as poor bioavailability and propensity to be rapidly 
metabolized, over 100 peptidic and macrocyclic drugs are currently on the 
market,6,18,19 and the present approval rate of peptide drugs is twice as high as that 
of small molecule-based drugs.20 Owing to the fast growing attention of bridging 
the gap between traditional small molecule and large biological drugs, the 
understanding and the ability of predicting the behavior of cyclic peptides and 
other macrocycles is of utmost importance. 
 
2.1 Solution conformation 
Macrocycles are usually flexible molecules and a variety of conformers are thus 
present in solution. It has been shown that due to this flexibility, the population of 
the bioactive conformation of macrocycles can be as small as 4% in solution.21 
Further, in contrast to small molecule-based drugs, the solution conformations of 
peptidic drugs have been proposed to be even more important than their 
physiochemical properties in order to gain high bioactivity and bioavailability.17 
Truncated peptide fragments from proteins usually do not retain their native 
conformation and consequently lose their binding affinity. Therefore, peptides are 
often modified with the aim of reinforcing their native conformation and of 
restoring their binding affinity towards their protein targets, for example via 
cyclization.16 There are numerous examples of the introduction of conformational 
constrains that lock them into a defined secondary structure,17,22 including stapled 
α-helices23,24 azide-alkyne 1,3-dipolar cycloaddition25 and cysteine- or triazole-
bridged β-hairpins.26 Since most of the work in this thesis is based on the β-hairpin 
secondary structure, it is described in more detail below. 
 
2.1.1 The β-hairpin structural motif 
A β-hairpin consists of two antiparallel hydrogen bonded β-strands, connected by a 
type I’ (i+1 = 60°, i+1 = 30°, i+2 = 90°, i+2 = 0°) or a type II’ (i+1 = 60°, i+1 = 
-120°, i+2 = -80°, i+2 = 0°) β-turn (Figure 1).27 It is a common motif in proteins, 
often involved in molecular recognition events such as protein-DNA, protein-
RNA, and protein-protein recognition.28,29 β-Hairpins have, for example, been 
studied as inhibitors of PPIs,30 antimicrobial agents,31 and protease inhibitors.32 
 
 
 
Figure 1. Schematic representation of a β-hairpin. The loop positions are shown in purple and 
backbone hydrogen bonds in green. The backbone dihedral angle used in the Karplus equation 
(JHH’ = A + B cos C cos 2 is shown in blue. 
 
In addition, β-hairpins are suitable model systems for studying the early stages of 
protein folding33 and as models for investigation of weak interactions.34,35 The first 
small linear peptide that folds into β-hairpin in solution was reported in 1993,36 and 
since then a large number of β-hairpin models have been described.27,28,33 However, 
the high tendency to aggregate and the low conformational stability of isolated 
linear β-hairpins, makes their investigation challenging. Consequently, large efforts 
have been made to determine the driving forces of β-hairpin folding and to find β-
hairpin stabilizing elements, some of which are described below. 
 
2.1.2 Design of β-hairpins stable in solution 
β-Hairpin formation is the result of the cooperative interplay of several factors.27,33 
These include the conformational directing ability and rigidity of the β-turn, the 
propensity of the strand residues to adopt an extended conformation, the presence 
of stabilizing side chain cross strand interactions, and backbone hydrogen bonds. 
 
2.1.2.1 Turn sequence 
The β-turn has a backbone hydrogen bond between residues i and i+3, as 
illustrated in Figure 1.37 There are several types of turn structures with a variety of 
amino acid combinations known to have high propensity of forming β-turns. Some 
common examples are D-Pro-Gly,38,39 Gly-Asp,40 Asn-Gly,39 and D-Pro-L-Pro.28,41,42 
The turn sequence is proposed to play a major role in the folding propensity for β-
hairpins.37,38 
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 2.1.2.2 β-Sheet forming propensities of amino acids 
Various amino acids have a different tendency to form the β-sheets of β-hairpins. 
Especially β-branched amino acids such as Val, Ile and Thr favor β-sheet 
formation.43,44 Other amino acids that are also commonly found in β-sheets are 
Phe, Tyr and Trp. The amino acids with least β-sheet forming tendency are Ala, 
Asp, Gly, and Pro,43 which, on the other hand, are commonly found in β-turns. 
 
2.1.2.3 Interactions between side chains 
Cross strand side chain to side chain interactions are commonly used to improve β-
hairpin stability.45 These interactions can be either hydrophobic or polar, and some 
common examples are the “tryptophan zipper” encompassing cross strand 
tryptophan residues,46 aromatic π-interactions,47 and electrostatic interactions.27,33,48 
 
2.1.2.4 Backbone hydrogen bonds 
The backbone hydrogen bonds of β-hairpins usually only have a weak stabilizing 
role, and their influence is not fully understood.27,33 The stabilization of backbone 
hydrogen bonds are related mainly to the turn regions.33 Nevertheless, backbone 
hydrogen bonding is part of the definition of the β-hairpin structural element, as 
shown in Figure 1. 
 
  
 
3. Conformational analysis of flexible systems 
Some commonly used techniques to gain insight into the conformational behavior 
of molecules are X-ray diffraction,49 Raman spectroscopy,50 IR spectroscopy,51 MM 
and MD calculations,52-54 CD spectroscopy,42,55 cryo-EM,56 and NMR 
spectroscopy.57 Of the experimental methods, CD and IR/Raman give information 
on the overall conformation, whereas NMR and X-ray diffraction provide atomic 
level data. Cryo-EM also gives detailed information, although this rather new 
technique has not yet found the same widespread use as NMR spectroscopy and X-
ray diffraction.56,58 The bioactive conformation of ligands is usually derived from X-
ray crystallography, but the flexibility of a molecule in solution is better explored by 
NMR spectroscopy. An important and often ignored aspect of NMR spectroscopy 
is that the signals are averages of all the conformations of the studied molecule that 
are present, weighted with their corresponding molar fractions. Therefore, when 
presuming a single conformation only, NMR data in combination with MM or MD 
calculation may give misleading geometries. For its proper interpretation, the 
observed data have to be analyzed as the population averaged sum of the data of 
single conformations.59,60 The NMR analysis of molecular flexibility in solution 
(NAMFIS)61 method can deconvolute the NMR data into the present conformers, 
as described in section 3.2 below. 
 
3.1 Peptide NMR spectroscopy 
The two most commonly used 2D NMR techniques for studying the primary 
structure of peptides are Total Correlation Spectroscopy (TOCSY) and Nuclear 
Overhauser Effect Spectroscopy (NOESY).59 TOCSY gives correlations for all 
protons that belong to the same spin system, in other words through-bond 
correlations via spin-spin coupling. NOESY correlates protons through dipolar 
couplings in space, i.e. protons that are not covalently bonded. The NOE effect is 
scaled by 1/r6, where r is the distance between two protons and typically distances 
up to ~5 Å can be detected. The NOE signal also depends on the motion of the 
molecule, which is dependent on the size and the shape of the molecule, viscosity 
of the solution, temperature, and magnetic field strength.62 The signal dependence 
of the molecular motion is illustrated in Figure 2 A. The phase of small, fast 
tumbling molecules is usually of opposite sign as compared to the diagonal peaks 
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 and the NOE has a maximum possible value of +0.5. For large slow tumbling 
molecules the phase is usually of the same sign as compared to the diagonal peaks 
and the NOE has a maximum of -1.0. As shown in Figure 2 A. intermediate size 
molecules (~1000–2000 Da) might give very weak or no NOE signals at all.62 Due 
to the 1/r6 signal dependence of the NOE signal, interproton distances can be 
calculated from NOE measurements (Figure 2 B), as described in section 3.1.3 
below. 
 
Figure 2. The magnitude of NOE depends on molecular and experimental factors. A. The 
dependence of the signal intensity on molecular motion (τc = correlation time, i.e. the time 
required for a molecule to rotate one radian (2π/360°), ω0 = spectrometer observation 
frequency). Small molecule NOE signals are positive with a maximum possible value of +0.5 
(+50%). Large molecule NOE signals are negative with a maximum possible value of -1 (-100%). 
Intermediate size molecules might give zero NOE. B. The build-up of the NOE signal as a 
function of mixing time (full line) and the initial rate approximation (dashed line). 
 
3.1.1 Peptide 1H NMR assignment 
The chemical shift of peptide protons are usually assigned with the TOCSY-
NOESY sequential backbone walk.63 A TOCSY spectrum gives characteristic peak 
patterns for each amino acid in the peptide. Starting from an NH diagonal peak 
following f1 or f2, all cross peaks in the spin system for a given amino acid can be 
detected. Correlations to the next amino acid in the sequence can then be found in 
the corresponding NOESY spectrum, and in this way all peptide protons can be 
assigned by “walking” through the backbone. 
 
 
3.1.2 Chemical shift and coupling constants related to secondary 
structure 
Proton chemical shifts are affected by the electron distribution, bond hybridization, 
proximity to polar groups, nearby aromatic rings, and bond magnetic anisotropy, 
but are also sensitive to molecular conformation and environment.64,65 The 1H and 
13C chemical shifts of peptides give information on their secondary structure. 
Protons in β-strands are more deshielded (higher chemical shifts), as compared to 
the chemical shifts of random coils. Analogously, protons in α-helices are more 
shielded (lower chemical shifts), as compared to those of random coils.64 There is 
also a relationship between 3JNHCαH coupling constants and secondary structure: 
larger couplings are obtained for β-sheets as compared to α-helices.66 The 3JNHCαH 
for peptides can be transformed to the corresponding dihedral angles (Figure 1, 
blue atoms) via a modified Karplus equation (3JHH’ = A + B cos C cos 2)67,68 
with A, B and C-constants optimized for amino acid side chain substitute effects.69 
 
3.1.3 Measuring interproton distances from NOESY 
The NOE is the result of dipolar cross-relaxation from nearby spins with perturbed 
energy levels. The magnitude of the observable NOE is proportional to the cross-
relaxation rate (σ) between the interacting spins.62 In the NOESY experiment there 
is a delay for evolution of the NOE transfer, in other words NOE signal build-up. 
This delay is also referred to as mixing time. As illustrated in Figure 2 B, the initial 
build-up (dashed line) is linear at short mixing times at which the observed signal 
intensity is determined by the cross-relaxation process. At longer mixing times, 
other relaxation mechanisms, such as spin diffusion, influence the relaxation and 
consequently the dependence of NOE intensity on the mixing time deviates from 
the initial linearity (Figure 2 B full line).59 In practice, a series of NOESY 
experiments with an array of mixing times are measured and the normalized peak 
areas for each mixing time at the initial linear part of the buildup curve calculated 
according to eq. 170 
 
Peak Area= ( Cross peak 1 × Cross peak 2
Diagonal peak 1 × Diagonal peak 2
)
0.5
 (eq. 1) 
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 and then plotted against the mixing times. The slope of the initial linear part of the 
build-up curve (Figure 2 B, dashed line) corresponds to the cross-relaxation rate σ, 
and from this the interproton distances can be calculated according to eq. 2 
 
rij= rref × (
σref
σij
)
(1/6)
 (eq. 2) 
 
where rij is the distance between protons i and j, rref is the distance for a pair of 
reference protons (geminal CH2 = 1.78 Å or aromatic H-C=C-H = 2.51 Å), and σref 
and σij are the corresponding build-up rates. 
 
3.1.4 Variable temperature NMR spectroscopy  
The temperature dependence of the chemical shift of the proton of a peptide 
involved in a two-state equilibrium process can be measured by variable 
temperature NMR (VT NMR), as is illustrated in Figure 3 (dashed curve). Peptides 
are typically flexible and exist as an ensemble of conformations in solution, and 
accordingly their observed chemical shifts are the population weighted averages of 
all conformations that are present at a certain temperature.59 Upon temperature 
variation, they show broad transition curves where the fully folded state is usually 
not reached even at low temperatures. Large proteins are typically less dynamic 
with well-defined folding states (solid curve, Figure 3),71 and it is therefore easier to 
determine their melting temperature (Tm). Even if the complete unfolded/folded 
states may not be reached for a small peptide fragment within an experimentally 
acsessible temperature interval, the data can be fitted to the equation describing the 
temperature dependence of the chemical shift (eq. 3). The melting temperature 
(transition temperature) Tm can thus be derived from  
 
δobs= δU+
δF-δU
exp[− ∆HmR (
1
T  − 
1
Tm
)]+1
 (eq. 3) 
 
where δobs is the observed chemical shift in ppm at the different temperatures (T), 
δF and δU are the chemical shift for the folded and unfolded states, respectively, and 
ΔHm is the enthalpy change for unfolding at the melting temperature Tm.72 
 
 
 
 
Figure 3. The chemical shift temperature dependence of proteins and peptides involved in a 
two-state conformational equilibrium process. Tm= unfolding temperature/melting temperature, 
i.e. the temperature at which 50% of the protein/peptide is unfolded. 
 
3.1.5 Backbone hydrogen bonding 
There are two routinely used methods to investigate backbone hydrogen bonding 
in peptides. The first method is by measuring the amide proton temperature 
coefficients (ΔδNH/ΔT), which are derived from the correlation of 1H NMR 
chemical shift and temperature. ΔδNH/ΔT of the backbone NH are obtained from 
(δT,high-δT,low)/(Thigh-Tlow) and typically provides negative values, which are 
conventionally reported as positive numbers.59 ΔδNH/ΔT < 3 indicates a strong 
intramolecular hydrogen bond, ΔδNH/ΔT = 3–5 indicates that the amide proton is 
in equilibrium between a solvent exposed and an intramolecular hydrogen bond, 
and ΔδNH/ΔT > 5 that the amide proton is solvent exposed.59,73,74 The temperature 
dependence is usually linear to about 15 °C below the melting temperature for the 
peptide (Figure 3).65 The change in chemical shift is a result of the change in 
shielding of the proton due to the hydrogen bond. Hence, a hydrogen bonded 
backbone amide causes the proton to be deshielded. Increasing the temperature 
leads to weakening of the hydrogen bond interaction, higher shielding of the amide 
proton, and a lower chemical shift.65 The change in amide proton shift is typically 
also a result of loss in secondary structure, in other words unfolding of the peptide. 
The second method to obtain information about backbone hydrogen bonds is by 
measuring the amide exchange rate, i.e. the exchange rate of the amide protons for 
deuterium when adding a deuterated protic solvent.59 Exchange rates are sensitive 
to pH and local structure fluctuations, and are best used in combination with amide 
proton temperature coefficients.65 
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determine their melting temperature (Tm). Even if the complete unfolded/folded 
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(transition temperature) Tm can thus be derived from  
 
δobs= δU+
δF-δU
exp[− ∆HmR (
1
T  − 
1
Tm
)]+1
 (eq. 3) 
 
where δobs is the observed chemical shift in ppm at the different temperatures (T), 
δF and δU are the chemical shift for the folded and unfolded states, respectively, and 
ΔHm is the enthalpy change for unfolding at the melting temperature Tm.72 
 
 
 
 
Figure 3. The chemical shift temperature dependence of proteins and peptides involved in a 
two-state conformational equilibrium process. Tm= unfolding temperature/melting temperature, 
i.e. the temperature at which 50% of the protein/peptide is unfolded. 
 
3.1.5 Backbone hydrogen bonding 
There are two routinely used methods to investigate backbone hydrogen bonding 
in peptides. The first method is by measuring the amide proton temperature 
coefficients (ΔδNH/ΔT), which are derived from the correlation of 1H NMR 
chemical shift and temperature. ΔδNH/ΔT of the backbone NH are obtained from 
(δT,high-δT,low)/(Thigh-Tlow) and typically provides negative values, which are 
conventionally reported as positive numbers.59 ΔδNH/ΔT < 3 indicates a strong 
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The second method to obtain information about backbone hydrogen bonds is by 
measuring the amide exchange rate, i.e. the exchange rate of the amide protons for 
deuterium when adding a deuterated protic solvent.59 Exchange rates are sensitive 
to pH and local structure fluctuations, and are best used in combination with amide 
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 3.2 NMR analysis of molecular flexibility in solution  
Molecules exist in a variety of conformations in solution. The molar fractions of 
these conformations (the Boltzmann distribution), are determined by their relative 
free energies. This means that the solution conformation cannot be accurately 
represented by a single structure derived from experimentally restrained structure 
calculations60 such as restrained MD or MM, but rather by a solution 
conformational ensemble. The NAMFIS method61 deconvolutes time-averaged 
NMR variables (NOE distances and scalar couplings) into the solution ensemble, 
fulfilling all structural restraints. In practice, NAMFIS varies the mole fraction of 
each conformer in a computed theoretical input ensemble until the best possible fit 
to the experimental data is obtained. In this way, those conformers that exist in 
solution are given a probability that corresponds to their molar fraction, and all 
other conformations are assigned zero probability. In contrast to conformational 
analysis using NMR data as constrains in the computation, providing one averaged, 
possibly unreal conformation, NAMFIS finds all conformations that exist in the 
solution ensemble (Figure 4). Since energies are not considered in the NAMFIS 
analysis, the “energy catastrophe”, i.e. energy misevaluation introduced by long-
range interactions among polar functionalities, is avoided.75 NAMFIS has 
previously been utilized to determine the solution conformation of peptides,76,77 
macrocycles21,78,79 and small molecules.75,80,81 
 
The reliability of the NAMFIS analysis depends on the quality of the NMR-derived 
distances and dihedral angles, as well as that of the theoretical ensembles.75 In order 
to obtain high quality NOE-based distances, the following should be implemented: 
- At least 4 different mixing times. 
- All NOESY experiments should be run subsequently, in a queue. 
- The mixing times should be alternated to get rid of systematic errors. 
- Applied parameters have to be identical, as do the processing of spectra. 
- Temperature control should be active and water presaturation should be avoided. 
 
 
Figure 4. Comparison of methods for analysis of solution conformation. A. Constrained 
computational conformational analysis. B. NAMFIS. 
 
The conformational search, giving the theoretical input ensemble for NAMFIS 
analysis, should cover the entire available conformational space. In practice this is 
challenging, but a large number of steps and a reasonable energy window should 
capture most of the possible conformations. To estimate the probability that a 
conformational search is complete the equation 1-(1-(1/N))M can be used, where N 
is the total number of conformers and M is the number of search steps.75 
Moreover, finding the 10 “lowest energy” conformations at least 5 times each is a 
reasonable indicator that a sufficient conformational search has been performed. 
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 4. Peptide synthesis 
Peptides are synthesized by linking two amino acids (Appendix I) by an amide 
bond in a condensation reaction. The general peptide coupling reaction of two 
amino acids, generating a dipeptide, is outlined in Scheme 1. 
 
 
 
Scheme 1. General outline of the peptide bond formation. AG = activating group, PG = 
protecting group. 
 
At ambient temperature, the reaction can only occur if the carboxy component of 
one of the participating amino acids is activated as a good leaving group (Scheme 1, 
blue square, AG = activating group), and can then react with the amino component 
of the other amino acid and form the amide bond.82 Activation can be achieved by 
the use of coupling reagents, as described in section 4.4 below. In order to get a 
controlled reaction with only the desired product, all other amino and carboxy 
functions in the reaction have to be protected (Scheme 1, green square, PG = 
protecting group). This is also true for reactive groups at side chain positions 
(Scheme 1, R1 and R2). The most commonly used protecting group strategy, the 
Fmoc/t-Bu method, is described in section 4.2 below. For side chain protection 
there are a large number of protecting groups to choose from.83 
 
4.1 Solid phase peptide synthesis 
Solid phase peptide synthesis (SPPS) was first described by Bruce Merrifield in 
1962,84 and he was later awarded the Nobel Prize for this discovery. Today, SPPS is 
the most common strategy for peptide synthesis.85,86 In SPPS (Scheme 2) the first 
amino acid of the growing peptide chain is attached to an insoluble solid support 
via a linker. The advantage, as compared to solution phase peptide synthesis, is that 
byproducts and reagents can be washed off via filtration after each coupling, and 
time-consuming purification and isolation of intermediates can be avoided. The 
first step in SPPS is attachment of the C-terminus of the first amino acid to the 
linker. Subsequent deprotection of its N-terminal amine and coupling to the next 
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 amino acid in the sequence gives the dipeptide, as illustrated in Scheme 2. The 
carboxyl group of the added amino acid is activated prior to the addition. After the 
coupling, the α-amino group is deprotected and can thus be coupled to the next 
amino acid. The procedure is repeated until the full linear sequence is obtained, and 
the resin is filtered and washed between each step. 
 
 
 
Scheme 2. General outline of solid phase peptide synthesis (SPPS). 
 
 
Lastly, the peptide is cleaved from the solid support and final deprotection of side 
chain protecting groups is performed. When a cyclic peptide is the final product, 
the side chain protecting groups are usually removed after cyclization. 
 
4.2 The Fmoc/t-Bu method 
As outlined in Scheme 2, the α-amino protecting group is removed after each 
coupling step and should therefore be orthogonal to the side chain protecting 
groups and the linker, in other words they should not be cleaved under the same 
reaction conditions. There are two commonly used protecting group strategies for 
SPPS: the Fmoc/t-Bu strategy and the Boc/Bn strategy (Figure 5). 
 
 
Figure 5. A. The Fmoc group is removed by base whereas the t-Bu side chain protection groups 
are removed under acidic conditions. Cleavage of the peptide is also performed under acidic 
conditions. B. The Boc group is removed under acidic conditions and the Bn group by 
palladium-catalyzed hydrogenation or strong acids. The peptide is cleaved from the resin using 
strong acid, typically HF.83 
 
Protecting the α-amino group with Fmoc provides an orthogonal deprotection 
scheme since Fmoc is deprotected with bases, usually piperidine, while the side 
chain protecting groups and the linker is normally cleaved under acidic conditions. 
In addition, removal of the Fmoc group is performed under milder conditions than 
the Boc group, which requires strong acid such as trifluoroacetic acid (TFA).85 
Since the Fmoc strategy has been used for the SPPS in this thesis, it is the only 
strategy that will be discussed further. Common side chain protection groups in the 
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 Fmoc/t-Bu strategy includes trityl (Trt for Asn, Cys, Gln, His), t-Bu (for Asp, Glu, 
Ser, Thr, Tyr), Boc (for Lys, Trp), and pentamethyl-2,3-dihydrobenzofuran-5-
sulfonyl (Pbf, for Arg).83,86 During SPPS, the Fmoc group is commonly removed by 
piperidine, which also acts as a scavenger for the generated dibenzofulvene.87 The 
mechanism for Fmoc cleavage is shown in Scheme 3. 
 
 
 
Scheme 3. Deprotection of the Fmoc group using piperidine as base and scavenger for the 
dibenzofulvene, which reacts with piperidine to form the fulvene-piperidine adduct. 
 
4.3 Resins and linkers 
The resins used in SPPS are usually polystyrene (PS)- or polyethylene glycol (PEG)-
based, and are available in different mesh sizes and with different linkers attached.85 
Before the first coupling the resin is allowed to swell in a suitable solvent. For PS 
resin, swelling is most effective in dichloromethane (DCM). Dimethylformamide 
(DMF) can also be used, which is also the preferred solvents for the coupling 
reactions. As illustrated in Scheme 2, the peptide is attached to the resin via a 
linker. There are a large number of linkers available for SPPS,85,86,88 and they differ 
in cleavage conditions, loading, distance between peptide and resin, and the C-
terminal functionality of the peptide product.86 Two common examples of PS-
based resins are shown in Figure 6. The 2-chlorotrityl linker is commonly cleaved 
under mild acidic conditions (1% TFA) providing a C-terminal carboxylic acid. The 
Rink amide resin is cleaved using higher concentrations of acid (50% TFA) 
 
providing the C-terminal amide. Both the 2-chlorotrityl and Rink amide resins have 
been utilized in this work. 
 
 
Figure 6. Two commonly used resins for SPPS. The 2-chlorotrityl chloride linker provides the 
C-terminal acid and Rink amide resin provides the C-terminal amide. 
 
 4.4. Coupling reagents 
As mentioned above, coupling reagents are used for activation of the carboxylic 
acid. The acid is transformed to an activated ester by introducing an electron 
withdrawing group that acts as a better leaving group (X, Scheme 4). The carbonyl 
is thereby available for reaction with the nucleophilic amine of the next amino acid.  
 
 
Scheme 4. The coupling reaction in SPPS, using a coupling reagent (X) in the presence of base 
to activate the carboxylic acid. AG = activating group, PG = protecting group. 
 
There is a large number of commercially available coupling reagents.89 Examples of 
coupling reagents often used are shown in Figure 7. The carbodiimides N,N'-
diisopropylcarbodiimide (DIC) and N,N'-dicyclohexylcarbodiimide (DCC) belong 
to the first generation of coupling reagents, and are often used together with 
racemization suppressants such as 1-hydroxybenzotriazole (HOBt) and 1-hydroxy-
7-azabenzotriazole (HOAt).86 As shown in the coupling mechanism in Scheme 5, 
uronium/aminium-based 3-[bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-
oxide tetrafluoroborate (TBTU) or 3-[bis(dimethylamino)methyliumyl]-3H-
benzotriazol-1-oxide hexaﬂuorophosphate (HBTU) generate HOBt in situ. 
Similarly, for 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxide hexafluorophosphate (HATU), HOAt is generated in the reaction. 
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Figure 7. Examples of peptide coupling reagents. 
 
The uronium/aminium-based coupling reagents are commonly used together with 
a tertiary amine such as diisopropyl ethyl amine (DIPEA). HATU is more reactive 
than TBTU and HBTU and as a result epimerization is therefore often avoided.85 
These reagents were first assigned as the O-isomers (uronium salts) but it was later 
shown that they exist as the N-isomer (aminium salt, Figure 7) both in solid state 
and in solution.90 Phosphonium salts such as benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOB, Figure 7) are also 
common coupling reagents. 
 
 
 
Scheme 5. Proposed mechanism of HBTU (X=PF6- )/TBTU (X=BF4- ) activation.85 
  
  
 
 
 
 
4.5 Peptide cyclization 
As discussed in Chapter 2, there are several beneficial properties gained by forming 
cyclic peptides and, as a result, they are valuable target molecules for medicinal 
chemists. Peptide cyclization is often difficult, mainly due to the entropically 
disfavored pre-cyclization conformation that the linear peptide needs to adopt, 
bringing the reactive ends in close spatial proximity, prior to cyclization.91 As a 
result dimerization or polymerization is often favored over cyclization. However, 
this can be avoided by running the cyclization reaction at low concentration. For 
peptide cyclization in solution, high dilution can be accomplished with slow 
addition by the use of syringe pumps. Pseudodilution can also be achieved using 
solid supported macrocyclization.92,93 Peptide cyclization can be performed head-
to-tail, side chain-to-tail, head-to-side chain or side chain-to-side chain.91,94  
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 5. Aims of the thesis 
The overall aim of this thesis work was to investigate the solution ensembles of 
macrocycles in order to gain knowledge on the conformation stabilizing effects of 
weak interactions and to evaluate the role of flexibility in bioactivity. 
 
The specific objectives were to:  
 
 design a cyclic β-hairpin model system for investigation of weak interactions. 
 investigate the ability of various methods for evaluation of this model 
system. 
 use the model system to study the impact of hydrogen and halogen bonding 
on β-hairpin folding. 
 investigate cyclic β-hairpins as inhibitors of the MDM2/p53 interaction and, 
in particular, examine if there is a correlation between activity and solution 
conformation. 
 describe the solution conformational ensembles of CD36 modulating 
macrocyclic azapeptides. 
 evaluate the conformational change of roxithromycin dependent on the 
hydrophobicity of the environment. 
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 6. Investigation of weak interactions using cyclic 
β-hairpin peptides as model systems (Papers I, II 
and III) 
 
6.1 Weak interactions in biological systems 
Molecular recognition of a ligand by its protein target relies on specific attractive 
weak interactions such as hydrogen bonding, hydrophobic forces, π-stacking, and 
halogen bonding.95,96 In drug design these interactions are optimized with the 
intention to improve affinity and selectivity, resulting in drug candidates with 
higher efficacy and fewer side effects. Weak interactions also direct protein folding. 
Since peptides are smaller, yet resemble proteins, they are commonly used as model 
systems for investigation of protein folding.27,33,97 Further, peptides have been used 
as models for investigations of weak interactions.34,35,98 Studying peptides by 
solution state experiments provides knowledge gained in a biological relevant 
environment. The information from studying weak interactions is useful, for 
example, for parametrization of the computational force fields for MD and MM 
algorithms and scoring functions for docking programs.99 
 
6.1.1 Hydrogen bonding 
A hydrogen bond is an attractive interaction between a hydrogen bond donor X-H 
and a hydrogen bond acceptor.100 Hydrogen bonds are the most frequently 
occurring interactions in biological recognition. Even though hydrogen bonds 
contribute to specificity for the target, the effect on the binding free energy is often 
low.95 This is due to the energy cost of desolvation of donors and acceptors that 
must take place before the binding event. Intramolecular hydrogen bonding can be 
utilized to increase membrane permeability of ligands.101 A survey of hydrogen 
bonds in the Cambridge Structural Database (CSD) and the Protein Data Bank 
(PDB) showed a median donor-acceptor distance of 2.75 Å for amide C=O and 
OH, and 2.9 Å for C=O and NH.95 The angle for donor−hydrogen…acceptor is 
generally above 150°.95 
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6.1 Weak interactions in biological systems 
Molecular recognition of a ligand by its protein target relies on specific attractive 
weak interactions such as hydrogen bonding, hydrophobic forces, π-stacking, and 
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low.95 This is due to the energy cost of desolvation of donors and acceptors that 
must take place before the binding event. Intramolecular hydrogen bonding can be 
utilized to increase membrane permeability of ligands.101 A survey of hydrogen 
bonds in the Cambridge Structural Database (CSD) and the Protein Data Bank 
(PDB) showed a median donor-acceptor distance of 2.75 Å for amide C=O and 
OH, and 2.9 Å for C=O and NH.95 The angle for donor−hydrogen…acceptor is 
generally above 150°.95 
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 6.1.2 Halogen bonding 
A halogen bond is an attractive interaction between an electron-poor region of a 
halogen atom and an electron donor.102 The electropositive region is termed a σ-
hole103,104 and is illustrated in Figure 8. The directionality and strength of halogen 
bonds can be tuned by changing the halogen atom (F ≪ Cl < Br < I). This is 
because the size of the σ-hole increases with polarizability and decreases with 
electronegativity.105 Generally, fluorine does not have a σ-hole and there are no 
examples of fluorine-mediated halogen bonds in biological systems. Given the 
relatively recent discovery of this interaction,102 the halogen bond is not as well 
described as the hydrogen bond. However, both theoretical and experimental 
studies have shown that the halogen bond is more directional than the hydrogen 
bond, and that the directionality also follows the trend Cl < Br < I, with donor-
acceptor angles approaching 180°.105 Halogen bonds were found in protein-ligand 
complexes,106-108 and over 50% of molecules in high throughput screening and 
~20% of all drugs are halogenated,109,110 motivating the investigation of this 
interaction. The σ-holes of chloro-, bromo- and iodo-substituted benzene are 
shown in Figure 8. 
 
 
 
Figure 8. The electropositive region (blue/green), i.e. the σ-hole, of chloro-, bromo- and iodo- 
substituted benzene, from left to right. 
 
6.2 Evaluation of the impact of interstrand hydrogen bonding 
on β-hairpin stability (Paper I) 
A peptidic model system (Figure 9 A) was designed for investigation of weak 
interactions. A ten amino acid cyclic β-hairpin was predicted to be a suitable model 
system, possessing two strands of three amino acids each connected by the two 
turns. Accordingly, if the β-hairpin conformation is adopted, the interaction site of 
interest (R3–R8) is positioned on one face of the peptide, as illustrated in Figure 9B. 
 
This design permits the selective study of the R3–R8 interaction without the 
influence of competing side chain to side chain interactions from other residues. 
Since the R3–R8 interaction is intramolecular, this model system offers an entropic 
advantage that allows the characterization of very weak forces. 
 
 
 
Figure 9. A. The β-hairpin model system with the interaction site R3–R8 in purple and other 
strand residues in blue. B. General outline of the β-hairpin model system shown from the side, 
with R3–R8 on one face of the peptide. For the hydrogen bonding peptide 1 R3=OH and R8=OH, 
and for the reference peptide 2 R3=OH and R8=Me. n=1 for 1 and 2. The amino acid (AA) 
position numbering is used for all peptides in Chapter 6. 
 
As a first step towards a β-hairpin model for investigation of halogen bonding, a 
system with a possible interstrand hydrogen bond was designed (1, Figure 9, 
R3=OH, R8=OH). The assumption that a R3–R8 hydrogen bond could be formed 
in this system was based on Monte Carlo molecular mechanics52 (MCMM) 
calculations. For examination of the stabilizing role of this single interstrand 
hydrogen bond on β-hairpin formation, peptide 1 was studied together with a 
reference containing a methyl at the R8-position (2, Figure 9, R3=OH, R8=Me), in 
which the R3–R8 interstrand hydrogen bond is absent. Any observed difference in 
the β-hairpin conformational stability of 1 and 2 is therefore expected to originate 
from the R3–R8 hydrogen bond of 1. 
 
The successful application of this model system relies on formation of a β-hairpin 
structure, and the first step was therefore to design a peptide that folds into this 
conformation. The structures of the hydrogen bond forming peptide 1 (R3= OH 
and R8=OH) and its reference 2 (R3=OH and R8=Me) are shown in Figure 10. In 
the design, the D-Pro–Gly turn inducer33,38 and a possible Val7 to Ala4 interstrand 
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the design, the D-Pro–Gly turn inducer33,38 and a possible Val7 to Ala4 interstrand 
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 hydrophobic interaction were included, which have previously been shown to be 
favorable for β-hairpin stabilization.33 In addition, since β-branched amino acids 
have shown high propensity in β-strands,43,44 an additional Val residue was 
incorporated. The model peptides were cyclized via a Gly–Asn weak turn inducer,40 
which was expected to increase the solubility of the peptides in polar solvents, as 
well as stabilize β-hairpin formation. 
 
 
 
Figure 10. The peptides used for investigation of the impact of an interstrand hydrogen bond on 
β-hairpin formation. Amino acids are given with three letter codes and residue positions. Abu = 
L-2-aminobutyric acid. 
 
6.2.1 Results and discussion Paper I 
The linear precursors of 1 and 2 were prepared by automated SPPS using an 
automated benchtop peptide synthesizer, on a 2-chlorotrityl resin following the 
Fmoc–t-Bu–Trt strategy.83,111 The peptide couplings were performed in DMF using 
the coupling reagent TBTU and the base DIPEA. Following cleavage of the t-
Bu/Trt-protected peptides from the solid phase with 1% TFA in DCM, the linear 
decapeptides were cyclized utilizing a “pseudo-high-dilution” procedure112 with 
HATU as the coupling reagent. Peptide cyclization is usually performed at 
submillimolar concentration in order to avoid dimerization or polymerization91 
leading to impractically high solvent volumes. By slow (10 μL/min) addition of the 
linear peptide precursor and the coupling reagent to the reaction mixture, low in 
situ concentration was obtained and minimal volume of solvent could be used. The 
side chain protecting groups were removed by TFA, and 1 and 2 were isolated 
following purification by reversed phase high performance liquid chromatography 
on a C18 column. The synthesis of 1 and 2 is outlined in Scheme 6.  
 
 
 
Scheme 6. Synthesis of 1 and 2. Reagents: (a) (i) 20% piperidine in DMF. (ii) Fmoc-AA-OH, 
TBTU, DIPEA. (iii) Acetic anhydride. Nine consecutive cycles with: Fmoc-Gly-OH, Fmoc-D-
Pro-OH, Fmoc-Val-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-
Asn(Trt)-OH, Fmoc-Val-OH, Fmoc-Ser(t-Bu)-OH (1) or Fmoc-Abu-OH (2) (b) (i) 20% 
piperidine in DMF. (ii) 1% TFA in DCM. (c) (i) HATU, DIPEA, DMF. (ii) TFA/H2O/TIPS 
(95:2.5:2.5). 
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 Structural assignment was carried out by the TOCSY-NOESY sequential backbone 
walk described in section 3.1.1. Due to the low water solubility, the experiments 
were performed in DMSO-d6. Both peptides had Hα chemical shifts and 3JCHαNH 
coupling constants (Table 1), as well as a NOE coupling pattern (Figure 11), 
compatible with β-hairpin conformation. Further, the low amide temperature 
coefficients (ΔδNH/ΔT) observed for Ala4 and Gln9 (Table 1 and Figure 11) 
confirmed formation of the two turn regions,65,73,113 as shown in Figure 11. 
 
Table 1. Hα proton chemical shifts (ppm), 3JCHαNH coupling constants (Hz) and ΔδNH/ΔT 
backbone amide temperature coefficients (ppb K-1) for 1 and 2 in DMSO-d6.  
Residue positiona δHα (ppm) 3JCHαNH (Hz) ΔδNH/ΔT (ppb K-1)b 
 
1 2 1 2 1 2 
Asn1 4.09 4.05 – 5.8 10.6 9.1 
Val2 4.18 4.20 8.6 8.9 6.5 5.7 
Ser3/Abu3 4.81 4.83 9.0 7.7 6.5 6.5 
Ala4 4.59 4.60 9.2 7.3 0.9 1.0 
Gly5 3.75, 3.51 3.75, 3.48 – – 6.4 6.4 
D-Pro6 4.27 4.27 – – – – 
Val7 4.29 4.30 9.5 9.7 6.4 5.7 
Ser8 4.49 4.51 – 7.8 7.3 7.1 
Gln9 4.51 4.55 9.2 – 1.3 1.1 
Gly10 3.85, 3.25 3.78, 3.22 4.4 5.8 4.1 5.2 
aResidue position according to Figure 9 A. bThe amide temperature coefficients are derived as 
negative numbers but reported as positive numbers. ΔδNH/ΔT < 3 indicates a strong 
intramolecular hydrogen bond, ΔδNH/ΔT = 3–5 indicates that the amide proton is in equilibrium 
between a solvent-exposed and intramolecular hydrogen bonded, and ΔδNH/ΔT > 5 indicate that 
the amide proton is solvent-exposed. 
 
To investigate the impact of the R3–R8 hydrogen bond on β-hairpin formation, the 
NAMFIS methodology, described in section 3.2, was used. Interproton distances 
and backbone CαH-NH dihedral angles were used as experimental input together 
with a theoretical MCMM-based ensemble of conformers. As described above, any 
difference of the β-hairpin population of 1 and 2 is presumed to result from the 
R3–R8 interstrand hydrogen bond. 
 
Interproton distances were measured from NOESY build-ups acquired with mixing 
times of 200, 400, 600, 700, 800, and 1000 ms, without solvent suppression, on a 
500 MHz spectrometer. The distances were calculated from the linear part of the 
 
build-ups (mixing time <800 ms), as described in section 3.1.3, using the geminal 
methylene protons Gly5-Hα, Gly10-Hα and Ser3-Hβ (1.78 Å) as internal distance 
references. The dihedral angles were calculated from 3JCHαNH using the Karplus 
equation developed specifically for peptides,69 as described in section 3.1.2. 
 
The theoretical conformational ensembles of 1 and 2 were generated by restraint-
free MCMM conformational searches with molecular mechanics energy 
minimization using the OPLS-2005 force field.114 Conformations within 42 kJ/mol 
of the global minimum were retained. The ensembles from the MCMM were then 
reduced by redundant conformation elimination with a root-mean-square deviation 
(RMSD) cutoff of 3 Å for heavy atoms. The derived ensembles were used together 
with the calculated backbone dihedrals and NOE build-up distances for the 
backbone positions of 1 and 2 in the subsequent NAMFIS analysis. Distances for 
side chain positions were not included in the initial run since the flexible side chains 
are not as well predicted as the backbone by MCMM calculations.52 
 
 
Figure 11. The NOE coupling pattern measured at 500 MHz (blue dotted lines) and amide 
backbone hydrogen bonds (green lines) for 1 and 2. 
 
NAMFIS analysis indicated peptides 1 and 2 to be folded into β-hairpin in 88% and 
55% molar fraction, respectively, in solution. This suggests that a single interstrand 
hydrogen bond provides a significant stabilization of this β-hairpin conformation. 
The β-hairpin conformation of 1, with the R3–R8 hydrogen bond, is shown in 
Figure 12 A. It should be noted that both peptides have unusually high tendency to 
fold, as previously described small peptides typically show <40% folding into β-
hairpin conformation in solution.33,73 The NAMFIS analysis was validated using 
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55% molar fraction, respectively, in solution. This suggests that a single interstrand 
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Figure 12 A. It should be noted that both peptides have unusually high tendency to 
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 standard methods, that is by random removal of experimental data, by adding 
random noise to the data, and by comparison of the experimental and back 
calculated distances and dihedrals. As shown in Figure 12 B, the folded 
conformations of 1 and 2 are highly similar. 
 
 
Figure 12. A. The β-hairpin conformation of 1, as selected by the NAMFIS analysis. B. Overlay 
of the major conformations of 1 (red) and 2 (blue). 
 
Attempts to derive the 1HNMR chemical shift temperature dependence of 1 and 2 
failed due to signal overlaps and small chemical shift changes for the available 
temperature interval. The Tm could only be derived for a limited number of 
residues and with large standard errors.  
 
6.2.2 Summary Paper I 
Two cyclic peptides, 1 and 2, differing only in an OH-to-Me substitution were 
synthesized and analyzed by NMR spectroscopy. Their solution conformational 
ensembles were derived from NAMFIS analysis, and it was shown that a single 
interchain hydrogen bond provided significant stabilization of the β-hairpin 
conformation. These results confirm that a cyclic β-hairpin model system is suitable 
for the investigation of weak interactions. 
 
 
6.3 Evaluation of the ability of spectroscopic methods to assess 
the difference in folding of β-hairpins (Paper II) 
The next pair of cyclic peptides that were designed, synthesized and evaluated is 
shown in Figure 13. As a step towards a model system for the investigation of 
halogen bonding, the R8 OH of 1 and 2 were substituted for OMe, generating 
peptides 3 and 4 (Figure 13). This design prevents competing hydrogen bonding 
 
when R3 is halogenated. However, this model system was first used for evaluating 
the ability of chemical shift melting curve analysis, as well as CD spectroscopy to 
quantitatively evaluate minor differences in hairpin folding. We have previously 
shown that MD calculations are capable to quantitatively predict the β-hairpin 
population of 1 and 2 by validation against experimental data, i.e. NAMFIS 
analysis.115 
 
6.3.1 Results and discussion Paper II 
Peptides 3 and 4 were synthesized as described in section 6.2.1 and their synthesis 
is shown in Appendix II. Analogously to peptides 1 and 2 described above, 3 and 4 
(Figure 13) differ only in their R3 substituent (Figure 9). OH-substituted 3 can form 
a hydrogen bond with OMe at R8, whereas the Me-substituted 4 cannot. Similar to 
peptides 1 and 2 described above, any difference in their folding is assumed to be a 
result of the capability to form the R3–R8 interstrand hydrogen bond. 
  
 
 
Figure 13. The peptides used for evaluation of the ability of spectroscopic methods to determine 
the difference in folding. Amino acids are given with three letter codes and residue positions. 
Abu = L-2-aminobutyric acid. 
 
As previously described, conformations with ≥3 interstrand hydrogen bonds were 
defined as folded,115 and the MD calculation for this peptide pair proposed the β-
hairpin population to be 64% for 3 and 43% for 4. Peptides 3 and 4 were evaluated 
using NAMFIS, similarly to 1 and 2 as described above. NOESY data were 
collected at a 900 MHz spectrometer and the interproton distances were 
determined from build-ups acquired with mixing times of 100, 200, 400, 500, 600, 
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 and 700 ms. The NOE coupling pattern and amide backbone hydrogen bonds for 
3 and 4 are shown in Figure 14. Theoretical ensembles were derived in the same 
way as described above, with MCMM conformational searching using OPLS-2005 
and AMBER* force fields. The subsequent NAMFIS analysis showed 29% 
difference in folding of 3 (58% folded) and 4 (29% folded). The folded 
conformations selected by NAMFIS are shown in Figure 15. 
 
 
 
 
Figure 14. The NOE coupling pattern measured at 900 MHz (blue dotted lines) and amide 
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The CD spectrum of 3 shows a double minimum at 205 nm and 223 nm. Although 
sometimes mistaken for a helical peptide spectrum, the double minimum is 
common for β-hairpins with strong type II’ β-turns, where the 205 nm absorption 
band is from the II’ β-turn and the 223 nm band from the β-sheet.42 On the other 
hand, the CD spectrum of 4 does not show this double minimum, and in addition, 
3 shows a stronger molar ellipticity in the 220 nm region as compared to 4. These 
data indicate that 3 is folded into a β-hairpin to a higher degree than 4. To quantify 
the folded populations of 3 and 4, CD spectra were measured at 200-260 nm at a 
temperature interval of 80 ºC. The variable temperature CD (VT CD) spectra were 
deconvoluted into β-hairpin and random coil components using principal 
component analysis (PCA). For both 3 and 4, the β-hairpin CD band at 220 nm  
 
loses intensity at higher temperature, while the random coil band at 200 nm gains in 
intensity. The PCA analysis showed 13% more folded structure for 3 as compared 
to 4.  
 
 
Figure 15. The β-hairpin conformation of 3, as selected by the NAMFIS analysis. B. Overlay of 
the major conformations of 3 (red) and 4 (blue). 
 
The chemical shift temperature dependence of 3 and 4 was measured and analyzed 
using the chemical shift melting curve analysis method reported by Honda et al.,116 
which was described in section 3.1.4. Due to signal overlaps and small chemical 
shift changes for the available temperature interval, the 1H NMR data could not be 
used. Instead, the VT NMR analysis was based on the 13C labeled β-carbon of 
alanine in position 4 (Figure 13). The temperature dependence was studied at 25–
130 ºC and the data were fitted to eq. 3 (section 3.1.4) using computationally 
predicted chemical shifts for the fully folded and unfolded states (δF and δU,), i.e. 
the endpoints of the melting curve. Only a small part of the unfolding curve could 
be detected in the experimentally available temperature interval. The relative 
thermodynamic stability of 3 and 4 was obtained as the ratio of the unfolding 
constants 𝐾𝐾𝑈𝑈 =  𝐾𝐾𝑈𝑈3 𝐾𝐾𝑈𝑈4⁄ . KU was derived from equation 4. 
 
KU (δU 3 - δobs3 )(δobs4 - δF4 )= (δobs3 - δF3 )(δU4 - δobs4 )  (eq. 4) 
 
The plot of (δU 3 −  δobs3 )(δobs4 −  δF4 ) versus (δobs3 −  δF3 )(δU4 −  δobs4 ) gives a close to linear 
correlation with the slope KU. The analysis suggests 4 to have 37% higher stability 
than 3. This is in disagreement with the outcome of the NAMFIS, MD and VT CD 
analyses. A likely explanation is that the first three methods describe the overall 
conformational change, whereas the chemical shift melting curve analysis of a 
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 single nucleus might predominantly report on local conformational changes, rather 
than on overall folding. 
 
6.3.2 Summary Paper II 
Evaluation of the ability of chemical shift and CD melting curve analyses to 
estimate the β-hairpin folding propensity, validated against MD and NAMFIS, 
suggest that the methods detecting the overall conformation (MD, VT CD and 
NAMFIS) detect 3 to be folded to a higher degree than 4. In contrast, chemical 
shift analysis of a single nucleus gave the opposite result. Hence, the method used 
for estimation of β-hairpin population must be chosen with care, and methods that 
may report on local rather than global conformational changes should be avoided.  
  
 
6.4 Evaluation of the impact of interstrand halogen bonding on 
β-hairpin stability (Paper III) 
Approximately 20% of all marketed drugs are halogenated.110 However, halogen 
bonding is not as well described in the literature as for example hydrogen bonding. 
So far, most studies of halogen bonds have been performed in the solid state (X-
ray) or by computations.105 The reported solution experiments have typically used 
small perfluorinated organohalides,117-119 which are not directly relevant for 
biological systems. Halogen bonding has to some extent also been studied in 
biological systems, for example in ligand-receptor recognition106 and to induce 
DNA junctions,120 but never before to modulate the conformation of a peptidic 
model system in solution. 
 
6.4.1 Results and discussion Paper III 
In addition to the peptides described in sections 6.2 and 6.3, two additional peptide 
pairs (5–6 and 7–8, Figure 16) were evaluated as possible models for studying 
halogen bond interactions. Their synthesis is outlined in Appendices III-IV. 
Hydrogen bonding peptide 5 and its reference 6, as well as hydrogen bonding 
peptide 7 and its reference 8, were designed to gain an overall increased flexibility 
as compared to peptides 1–4. In addition, an L-methoxy serine to L-methoxy 
homoserine substitution was performed, extending the side chain of R8 with an 
 
extra carbon (n=2, Figure 9 A and Figure 16). However, these changes led to a 
substantial destabilization of the peptides (Table 3). Linear peptides 5 and 6 do not 
fold into β-hairpin to a measurable extent, and cyclic peptides 7 and 8 do not show  
 
 
 
Figure 16. The additional peptides evaluated as possible halogen bond models. Amino acids are 
given with three letter codes and residue positions. Abu = L-2-aminobutyric acid. 
 
a sufficient difference in folding for the hydrogen bonding peptide (7, R3=OH, 
36%) and the reference (8, R3=Me, 30%), suggesting that the interstrand R3–R8 
hydrogen bond in this case is not formed. The NOESY coupling pattern and 
backbone NH coefficients of 5–8 are shown in Figure 19, and the results of all 
peptides (1–8) described so far are shown in Table 3. Considering all information 
collected for 1–8, peptide 3 was used as a template for the halogen bonding 
analogues. With 58% β-hairpin stability in solution for 3 (R3=OH, R8=OMe) as 
compared to 29% for the reference 4 (R3=Me, R8=OMe), this peptide pair is in a 
suitable folding region for a model system. Its chlorine- and bromine-substituted 
36
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 analogues (9 and 10, Figure 17) were therefore synthesized, and subsequently 
evaluated using NAMFIS. 
 
 
 
Figure 17. The halogenated analogues of 3. Amino acids are given with three letter codes and 
residue positions. 
 
The synthesis of the chlorine-substituted analogue 9 is outlined in Scheme 7. The 
first eight amino acids were coupled using SPPS, with an automated synthesizer, as 
described above. In order to avoid elimination of the Cl-atom, the last two 
couplings were performed manually under optimized conditions. HATU in 
combination with 2,4,6-trimethylpyridine (TMP) was found to give full conversion 
without any elimination product, as detected by LCMS. For removal of the Fmoc 
protecting group, a quick addition of 20% piperidine (1 min) in DMF gave the best 
result, however, still with some β-eliminated byproduct. After the last coupling the 
peptide was cleaved from the solid support as described above and was cyclized in 
solution using the same pseudo high dilution protocol112 as before, and 
HATU/TMP as reagents. The Hα chemical shifts, the 3JCHαNH coupling constants 
(Table 2) and the NOE coupling pattern (Figure 19) of 9 were in good agreement 
with a β-hairpin conformation. Ala4 and Gln9 showed low amide temperature 
coefficients (ΔδNH/ΔT, Table 2 and Figure 19), which confirmed the presence of 
the two β-turn regions, and hence a similar folding to the previously synthesized 
analogues. 
 
 
 
 
 
 
Scheme 7. Synthesis of 9. Reagents and reaction conditions: (a) (i) Fmoc-AA-OH, TBTU, 
DIPEA. (ii) Acetic anhydride. (iii) 20% piperidine in DMF. Seven consecutive cycles with: Fmoc-
D-Pro-OH, Fmoc-Val-OH, Fmoc-Ser(Me)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-
Asn(Trt)-OH, Fmoc-Val-OH, (b) (i) Fmoc-Ala(3-Cl)-OH, HATU, TMP. (ii) 20% piperidine in 
DMF, 1 min. (iii) Fmoc-[3-13C]-Ala-OH, HATU, TMP. (iv) 20% piperidine in DMF, 1 min. (v) 
1% TFA in DCM. (c) (i) HATU, TMP, DMF. (ii) TFA/H2O/TIPS (95:2.5:2.5). 
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Table 2. Hα proton chemical shifts (ppm), 3JCHαNH coupling constants (Hz), and ΔδNH/ΔT 
backbone amide temperature coefficients (ppb K-1) for 9 in DMSO-d6. 
Residue positiona δHα (ppm) 3JCHαNH (Hz) ΔδNH/ΔT (ppb K-1)b 
Asn1 4.07 6.75 6.52 
Val2 4.19 8.44 3.44 
Ala(Cl)3 5.25 8.45 5.20 
Ala4 4.66 8.28 1.28 
Gly5 3.84, 3.39 – 3.40 
D-Pro6 4.29 – – 
Val7 4.30 7.98 3.48 
Ser8 4.80 7.80 5.36 
Gln9 4.53 8.44 1.68 
Gly10 3.84, 3.25 – 6.68 
aPosition according to Figure 9 A. bThe amide temperature coefficients are derived as negative 
numbers but reported as positive numbers. ΔδNH/ΔT < 3 indicates a strong intramolecular 
hydrogen bond, ΔδNH/ΔT = 3–5 indicates that the amide proton is in equilibrium between a 
solvent-exposed and an intramolecular hydrogen bond, and ΔδNH/ΔT > 5 indicate that the amide 
proton is solvent-exposed. 
 
The solution conformational ensemble of 9 was derived by NAMFIS analysis, as 
described for the other peptides. Interproton distances were calculated from 
NOESY build-ups acquired with mixing times 200, 300, 400, 500, 600, and 700 ms, 
at a 900 MHz spectrometer. To generate the theoretical conformational ensemble, 
MCMM calculations were performed, using OPLS-2005, AMBER* and OPLS-3 
force fields. OPLS-3 is the first force field parameterized for halogen bonding, 
although so far only for halogens attached to aromatic rings.121 Due to the lack of 
force field parameters for aliphatic halogens, no conformations with the R3–R8 
interstrand halogen bond were observed in the MCMM calculation. Therefore, a β-
hairpin conformer encompassing a Cl–OMe distance and angle optimal for halogen 
bonding, enforced by restraints, was also added to the NAMFIS input ensemble. 
The total β-hairpin content in solution for 9 (R3=Cl, R8=OMe) was estimated by 
NAMFIS to 74%, which is significantly higher than for the reference (R3=Me, 
R8=OMe, 29%) and close to the hydrogen bonded analogue 3 (R3=OH, R8=OMe 
58%). For peptide 3, the main conformer selected by NAMFIS is the one with a 
R3–R8 hydrogen bond interaction, even when data derived only from backbone 
positions is used. In the NAMFIS analysis of 9, the conformer minimized with a 
constrained Cl–OMe distance and angle (Figure 18) was found to have a content of 
 
9%. However, with the ensemble of 3 as input the conformation with the R3–R8 
interaction is selected as the major one. 
 
 
Figure 18. The solution conformer with an interstrand Cl…O halogen bond.  
 
To further analyze the presence of an R3–R8 halogen bond, a NAMFIS analysis was 
carried out with the NMR data of these residues only. A β-hairpin conformation 
that was obtained in the initial NAMFIS analysis was selected, and its R3 and R8 
side chains were rotated around their Cα–Cβ bond to generate the gauche+, 
gauche−, and trans conformers, providing an input ensemble of nine conformers 
(Appendix V). Independently of the NMR data assignment of the β-hydrogens (2 × 
2 possible solutions) the conformation with the MeO and Cl facing each other was 
found to have >90% probability. In addition, the methyl group of the R8-OCH3 
was used as a reporter for the R3X…R8OCH3 interaction (X = OH (3), Me (4) or 
Cl (9)). Since the chemical shift of nuclei neighboring an equilibrium process is 
expected to show comparably high temperature dependence, the chemical shift of 
the R8OCH3-protons was monitored for peptides 3, 4 and 9 in the temperature 
interval 25–100 °C. The temperature coefficients (ΔδCH3/ΔT) were calculated to 
0.07 ppb/K for 4, 0.19 ppb/K for 3, and 0.32 ppb/K for 9. Following the trends 
observed by NAMFIS for the β-hairpin solution population of the peptides, these 
data support the conclusion that a R3–R8 halogen bond is formed. This result was 
further confirmed by density functional theory calculations that showed that a σ-
hole is present on the Cl-atom of 9, and estimated the bond energy to be 6.1 
kJ/mol, which is in good agreement with the literature.122 
 
Since aliphatic carbon-bromine bonds are not compatible with the conditions for 
SPPS, the bromine atom of 10 was introduced in the last step via reaction of 3 with 
a Vilsmeier reagent (Scheme 8).  
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Scheme 8. Outline of the synthesis of 10 encompassing a bromo-substituent in position R3. 
 
The bromo-substituted peptide 10 was found to be unstable at room temperature 
and was therefore analyzed at -10 ºC, in DMF-d7. The NOESY coupling pattern of 
10 is shown in Figure 19. No interstrand NOEs indicating β-hairpin folding were 
observed. The backbone NH coefficients could not be derived due to the rapid 
degradation of 10 upon increasing the temperature. Likewise, the solution 
conformational ensemble could not be obtained since no reliable distances could be 
measured from the NOESY spectrum of 10 at -10 ºC. It was concluded that in the 
case with R3 = Br, the peptide is most likely not folded as a β-hairpin. This might 
be due to the size of the Br that does not allow interstrand interactions with a 
reasonable geometry for a β-hairpin. 
 
 
 
 
Figure 19. The NOE coupling pattern (blue dotted lines) and amide backbone hydrogen bonds 
(green lines) for peptides 5–9 were measured in DMSO-d6 at room temperature at a 900 MHz 
spectrometer. The NOE coupling pattern (blue dotted lines) for peptide 10 was measured at -10 
ºC in DMF-d7 at a 500 MHz spectrometer. Amide backbone hydrogen bonds were not obtained 
for 10 due to rapid decomposition at temperatures > -10 ºC. 
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 Table 3. Summary of the results of the conformational analysis of peptides 1–10.  
Peptide Sequencea R3b R8b nc ΔδNH/ΔT < 3d % β-hairpine 
1 c(NVSAGD-PVSQG) OH OH 1 AA4, AA9 88 
2 c(NVXAGD-PVSQG) Me OH 1 AA4, AA9 50 
3 c(NVSAGD-PVS(Me)QG) OH OMe 1 AA4, AA9 58 
4 c(NVXAGD-PVS(Me)QG) Me OMe 1 AA4, AA10 29 
5 NVSAGD-PVhS(Me)QG-Ac OH OMe 2 – 11 
6 NVXAGD-PVhS(Me)QG-Ac Me OMe 2 – 0 
7 c(GQSAGD-PVhS(Me)AN) OH OMe 2 AA2, AA4, AA9 36 
8 c(GQXAGD-PVhS(Me)AN) Me OMe 2 AA2, AA4, AA9 31 
9 c(NVA(Cl)AGD-PVS(Me)QG) Cl OMe 1 AA4, AA9 74 
10 c(NVA(Br)AGD-PVS(Me)QG) Br OMe 1 n.d. n.d. 
aOne letter amino acid acronyms are given in Appendix I. Peptide sequence is given according to 
the numbering in Figure 9 A. X = Abu (L-2-aminobutyric acid), S(Me) = O-methyl-L-serine, 
hS(Me) = O-methyl-L-homoserine. bWhen R3=OH the R3–R8 hydrogen cross strand interaction is 
possible. When R3=Cl/Br the R3–R8 halogen cross strand interaction is possible. When R3=Me 
the cross strand interaction cannot occur, and the peptides with R3=Me serves as references. 
cNumber of carbons in the R8 side chain, see Figure 9. dΔδNH/ΔT < 3 indicate a strong 
intramolecular hydrogen bond (see section 3.1.5). AA positions are given in Figure 9. eThe % β-
hairpin in the solution ensemble as determined by NAMFIS analysis. Peptide 10 could not be 
evaluated due to rapid degradation at room temperature and low quality spectrum at low 
temperatures. 
 
6.4.2 Summary Paper III 
The impact of halogen bonding on β-hairpin formation in solution was studied by 
NMR, and it was concluded that a chlorine-centered halogen bond stabilizes a β-
hairpin to a comparable degree to an equivalent hydrogen bond. Since chlorine has 
poor NMR properties, the halogen bond was detected indirectly from 1H NOE/ 
NAMFIS ensemble analysis and VT NMR experiments. This is, to the best of our 
knowledge, the first example of a stabilizing halogen bond interaction in a peptidic 
system in solution. 
 
7. Conformational analysis of β-hairpin inhibitors 
of the MDM2/p53 protein-protein interaction 
(Paper IV) 
 
7.1 The protein-protein interaction 
Protein-protein interactions (PPIs) regulate numerous essential cellular pathways 
such as cell growth, DNA replication, transcriptional activation, energy production, 
protein folding, and transmembrane signaling, and are therefore important targets 
for the development of new therapeutics.123 However, due to their typically large 
and flat interaction sites, lacking well-defined buried cavities that are common for 
conventional targets, the activity of PPIs is often difficult to modulate by small 
molecules.124 In contrast to protein-small ligand interactions, which are typically 
mediated by a few specific chemical forces, the protein-protein complex formation 
is usually driven by a large number of weak interactions that are often hydrophobic. 
Peptides with well-defined secondary structures have been shown useful for 
modulation of targets with featureless and flat binding sites, like PPIs.16,125 This is 
because they can address the demand for higher molecular complexity that is 
necessary for targeting PPIs and hence reproduce the specific interactions involved, 
and thereby bind with high specificity to the flat protein interface.16 The 
identification of hot spots, that is regions of the binding site that significantly 
contribute to the binding free energy, has been demonstrated to be a fruitful 
strategy for the identification of PPI modulators.126 Many PPI drug targets have hot 
spot regions with well-defined secondary structures such as α-helices and β-sheets. 
One example is the MDM2/p53 PPI site, where an α-helix of p53 binds to MDM2 
via a “hot spot triad” involving the three hydrophobic residues Phe19, Trp23 and  
Leu26 aligned on one face of the α-helical fragment (Figure 20 A and B).127 
 
7.2 The MDM2/p53 interaction 
The transcription factor and tumor suppressor p53 is activated in response to 
DNA damage and cellular stress. p53 induces cell cycle arrest and apoptosis, and 
thereby protects cells from malignant transformation.128 MDM2 serves as a 
negative regulator of the expression of p53.129 Inactivation of p53 by mutation or 
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 overexpression of MDM2 is one of the most common defects in human cancers.130 
The pharmacological disruption of the MDM2/p53 PPI may therefore allow p53 
induced cell cycle arrest and apoptosis, providing a strategy for treating this 
important class of tumors.  
 
 
Figure 20. A. Crystal structure of the α-helix of p53 binding to MDM2. The “hot spot triad” 
consisting of residues Phe19 (i), Trp23 (i+4) and Leu26 (i+7) of p53 are shown (PDB code: 
1YCR).127 B. The α-helical part of p53 that binds to MDM2, with i, i+4 and i+7 residues. C. 
Schematic illustration of an MDM2 inhibitor as a cylinder and the positions of the i, i+4 and i+7 
triad shown as spheres. 
 
A large number of inhibitors of the MDM2/p53 interaction have been developed, 
including small molecules131-133 and peptides.125 Although these inhibitors vary in 
structure they all orient the interacting substituents in the i, i+4 and i+7 positions 
as illustrated in Figure 20 C. 
 
7.3 Constrained bioactive peptides 
Constraining the peptide conformation can be a useful strategy in order to increase 
both bioactivity and bioavailability. In fact, the conformation has been suggested to 
be the most important factor for the bioactivity and bioavailability of peptides.17 
Since peptides are usually flexible, binding to the target receptor is associated with 
an energy penalty due to the loss in entropy. By locking the peptide into the 
bioactive conformation this penalty will be smaller. Some examples of different 
ways to constrain peptides are hydrocarbon stapling,134 backbone cyclization,91 and 
azide-alkyne cyclization.22,25 However, for non-conventional targets like PPIs this 
approach has been discussed,10,135-137 and it has been proposed that bRo5-ligands, 
 
for example peptides, should have an appropriate balance between flexibility and 
rigidity to bind to their targets.10  
 
7.4 Methods used for biological evaluation 
7.4.1 Surface plasmon resonance 
In the surface plasmon resonance (SPR) experiment direct binding of a ligand to its 
receptor is measured. The general principle is outlined in Figure 21. A gold coated 
glass chip immobilized with the protein is illuminated with polarized light. Part of 
the light is penetrating the surface as a so-called evanescent wave, and the energy of 
this wave is missing in the detector in a certain angle (SPR angle, Figure 21 A), 
which can be measured.133 The SPR angle is directly proportional to the amount of 
material on the surface. When a ligand is added the SPR angle is increased. This 
angle dependence is detected over time as illustrated by the sensogram in Figure 21 
B, from which the on- and off-rates can be extracted and thereby also the 
dissociation constant (KD).99 
 
 
Figure 21. Schematic illustration of the SPR experiment. A. I. The protein immobilized on the 
surface. II. Addition of a binding ligand leads to an increased SPR angle. III. The angle is 
decreased when the ligand is removed by washing. B. SPR sensogram. The change is measured in 
resonance units (RU, 1 RU = 1 pg/mm2).  
 
7.4.2 Fluorescence polarization 
In the fluorescence polarization (FP) experiment (Figure 22) fluorescently labeled 
ligands are excited with linear polarized light. Due to the movement of the 
molecules in solution between the excitation and emission, the light emitted by the 
ligands is of a different polarization.133 The change in polarization is proportional to 
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 molecular tumbling in solution. This means that a fluorescently labeled ligand-
protein complex emits light of different polarization than the free ligand, which 
tumbles faster in solution. Adding a fluorescently labeled ligand to the protein and 
then exchanging it for the ligands of interest provides a measure of exchange rate. 
In contrast to SPR, the FP experiment can therefore be used to measure 
competitive binding of a ligand to its receptor.99 
 
 
Figure 22. Schematic illustration of the FP-experiment. A fluorescently labeled ligand rotates 
faster when it is not bound to the protein. 
 
 
7.5 Evaluation of the flexibility of cyclic β-hairpin inhibitors of 
the MDM2/p53 protein-protein interaction (Paper IV) 
β-Hairpin peptides, similar to the ones described in Chapter 6, have been used as α-
helical mimetics to inhibit the MDM2/p53 interaction.30 A crystal structure of the 
peptide with highest affinity (11, Figure 23) of the investigated compounds showed 
that the binding conformation is a β-hairpin placing the interacting side chains in 
the i, i+4 and i+7 positions.30 Due to the similarity to our previously described 
peptides, and the fact that the interstrand hydrogen bond can be used for 
stabilization of β-hairpins, we decided to study whether the inhibitory potency of 
the β-hairpin inhibitors of the MDM2/p53 PPI depends on their flexibility. 
 
 
 
 
 
7.5.1 Results and discussion Paper IV 
The previously reported 11 (Figure 23)30,138 was used as a starting point for the 
design of new β-hairpin inhibitors of the MDM2/p53 PPI. Based on 
conformational analysis of several cyclic peptides by MCMM, 12 (Figure 23) was 
selected for its predicted high propensity to fold into a β-hairpin conformation.  
 
 
Figure 23. Structures of cyclic peptides studied as inhibitors of the MDM2/p53 interaction. 
Amino acids are given with three letter codes and residue positions (i = position 10, i+4 = 
position 8 and i+7 = position 7). 
 
Several small molecule inhibitors of MDM2/p53 have a 4-chlorophenyl in the i+4 
position, and it has been speculated that the chlorine atom is involved in a halogen 
Slow rotation Fast rotation
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 molecular tumbling in solution. This means that a fluorescently labeled ligand-
protein complex emits light of different polarization than the free ligand, which 
tumbles faster in solution. Adding a fluorescently labeled ligand to the protein and 
then exchanging it for the ligands of interest provides a measure of exchange rate. 
In contrast to SPR, the FP experiment can therefore be used to measure 
competitive binding of a ligand to its receptor.99 
 
 
Figure 22. Schematic illustration of the FP-experiment. A fluorescently labeled ligand rotates 
faster when it is not bound to the protein. 
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Figure 23. Structures of cyclic peptides studied as inhibitors of the MDM2/p53 interaction. 
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Several small molecule inhibitors of MDM2/p53 have a 4-chlorophenyl in the i+4 
position, and it has been speculated that the chlorine atom is involved in a halogen 
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 bond with MDM2. Therefore, 4-chloro-L-phenylalanine was incorporated at the 
i+4 position in 12, and an analogue with the stronger halogen bond donor bromine 
at the same position, i.e. 4-bromo-L-phenylalanine (13, Figure 23), was also 
prepared. For comparison to previous data, 14 (Figure 23) was also included in the 
analysis. Peptides 12–14 all have the possible cross strand hydrogen bond as well as 
the D-Pro-Gly β-turn inducer that was used in our previous peptides (Figure 10 and 
Figure 13). 
 
Peptides 11–14 were prepared by SPPS as described in section 6.2.1, and their 
synthesis is outlined in Appendices VI–VIII. Likewise, structural assignment, NOE 
build-up-based distances, amide temperature coefficients, and MCMM ensembles 
were derived as described above. The Hα chemical shifts, the 3JCHαNH coupling 
constants (Table 4) and the NOE coupling pattern (Figure 24) were in good 
agreement with a β-hairpin conformation for all peptides. The amide temperature 
coefficients (ΔδNH/ΔT, Table 4 and Figure 24) were > 3, indicating that the 
backbone hydrogens are in equilibrium between intra- and intermolecular (solvent) 
hydrogen bonding; however, the coefficients are lowest at the turn positions, 
indicating formation of stable β-turns. 
 
Table 4. Hα proton chemical shifts (ppm), 3JCHαNH coupling constants (Hz) and ΔδNH/ΔT 
backbone amide temperature coefficients (ppb K-1) for 11–14 in DMSO-d6.  
Residue 
positiona 
δHα (ppm)  3JCHαNH (Hz)  ΔδNH/ΔT (ppb K-1)b 
11 12 13 14  11 12 13 14  11 12 13 14 
1 4.22 3.51 3.52 3.52  – – – –  – 9.3 8.1 10.0 
2 4.46 4.22 4.22 4.20  – – – –  – – – – 
3 4.90 4.78 4.79 4.68  – 7.8 7.5 –  5.7 7.4 7.6 8.1 
4 4.83 4.85 4.86 4.70  – – 7.3 7.4  8.8 9.4 9.6 11.8 
5 4.76 4.56 4.56 4.67  8.4 7.4 8.2 –  4.8 3.2 3.1 5.5 
6 4.27 4.37 4.37 4.33  7.7 6.2 8.0 6.8  10.0 7.1 7.2 8.2 
7 3.48 3.65 3.64 3.64  – – – –  8.2 9.3 8.6 10.1 
8 4.67 4.54 4.54 4.57  7.3 7.4 8.6 7.3  6.7 6.2 6.1 8.5 
9 5.02 4.70 4.71 4.80  7.9 – 7.3 6.6  9.1 10.5 9.8 8.5 
10 4.82 4.78 4.78 4.77  8.9 7.5 9.2 8.5  3.7 3.5 3.7 3.7 
 aResidue position according to Figure 23. bThe amide temperature coefficients are derived as 
negative numbers but reported as positive numbers. ΔδNH/ΔT < 3 indicates a strong 
intramolecular hydrogen bond, ΔδNH/ΔT = 3–5 indicates that the amide proton is in equilibrium 
between a solvent-exposed and an intramolecular hydrogen bond, and ΔδNH/ΔT > 5 indicates 
that the amide proton is solvent-exposed. 
 
 
 
 
Figure 24. The NOE coupling pattern measured at 900 MHz (blue dotted lines) and amide 
backbone hydrogen bonds (green lines) for 11–14. 
 
The NAMFIS analysis revealed the folding propensity to follow the order 12 ≈ 13 > 
14 > 11 (Table 5). The main conformations of 11–14 as selected by NAMFIS are 
shown in Figure 25. 
 
The inhibitory activity was evaluated using FP and SPR assays. The FP assay 
measures displacement of Texas red labeled wild-type p53 peptide bound to 
MDM2, and in this case the activity order 11 > 14 > 13 > 12 was observed (Table 
5). Hence, the activity increases with increased flexibility of the structurally similar 
β-hairpins 11–14. This observation was further supported by the KD-values 
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 measured by SPR assays (Table 5). Whereas the backbone geometries of the 
peptides are comparable to the MDM2-bound crystal structure of 11, as shown in 
Figure 25, the peptides show different degree of flexibility. Thus, our data indicate 
that constraining the peptides decreases their affinity to MDM2. 
 
Table 5. The results from the NAMFIS ensemble analysis and the FP and SPR assays for 11–14. 
Peptide % β-hairpina 
IC50 (μM) FP-
assayb 
95% CI  
FP-assayc 
KD (μM)  
SPR-assayd 
11 24 2.86 1.61-5.10 0.127 ± 0.001 
12 61 23.94 7.72-74.30 7.00 ±0.1 
13 61 10.10 5.67-17.99 5.73 ±0.09 
14 39 7.56 3.42-16.69 2.50 ±0.02 
a% β-hairpin content in solution as deduced by NAMFIS analysis. bMDM2/p53 inhibitory activity 
observed in a FP-assay. cCI = confidence interval. dDissociation constant (KD) measured using a 
SPR-assay. 
 
 
 
Figure 25. β-Hairpin conformations as selected by NAMFIS. A. The main conformation of 12. 
B. Overlay of conformations 11 (blue), 12 (grey), 13 (orange), 14 (pink), and the MDM2-bound X-
ray structure of 11 (red) showing their similarity. C. Overlay of the β-hairpin selected for 11 by 
NAMFIS (blue), and the MDM2-bound crystal structure of 11 (red). D. Overlay of the β-hairpin 
selected for 12 by NAMFIS (grey), and the MDM2-bound crystal structure of 11 (red). 
 
 
 
 
7.5.2 Summary Paper IV 
Four peptide inhibitors (11–14) of the MDM2/p53 PPI were designed, synthesized 
and evaluated with respect to their conformational flexibility and inhibitory activity. 
Constraining the peptides was shown to decrease the affinity towards MDM2. The 
importance of flexibility of bioactive peptides for an optimal affinity has previously 
been discussed, especially for difficult protein targets like PPIs.10 It has been 
proposed that flexible binding domains might require flexible ligands, and that 
conformational restrictions could result in overall reduced entropy for the ligand-
bound complex.10,13,15,95 Thus, the binding to a relatively flat surface, such as a PPI 
binding site, might require sufficient flexibility in order to allow the necessary 
geometrical adjustments. Stabilizing the bioactive conformation of macrocyclic 
peptides was previously shown to have either favorable or unfavorable entropic 
consequences.136,139 
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 measured by SPR assays (Table 5). Whereas the backbone geometries of the 
peptides are comparable to the MDM2-bound crystal structure of 11, as shown in 
Figure 25, the peptides show different degree of flexibility. Thus, our data indicate 
that constraining the peptides decreases their affinity to MDM2. 
 
Table 5. The results from the NAMFIS ensemble analysis and the FP and SPR assays for 11–14. 
Peptide % β-hairpina 
IC50 (μM) FP-
assayb 
95% CI  
FP-assayc 
KD (μM)  
SPR-assayd 
11 24 2.86 1.61-5.10 0.127 ± 0.001 
12 61 23.94 7.72-74.30 7.00 ±0.1 
13 61 10.10 5.67-17.99 5.73 ±0.09 
14 39 7.56 3.42-16.69 2.50 ±0.02 
a% β-hairpin content in solution as deduced by NAMFIS analysis. bMDM2/p53 inhibitory activity 
observed in a FP-assay. cCI = confidence interval. dDissociation constant (KD) measured using a 
SPR-assay. 
 
 
 
Figure 25. β-Hairpin conformations as selected by NAMFIS. A. The main conformation of 12. 
B. Overlay of conformations 11 (blue), 12 (grey), 13 (orange), 14 (pink), and the MDM2-bound X-
ray structure of 11 (red) showing their similarity. C. Overlay of the β-hairpin selected for 11 by 
NAMFIS (blue), and the MDM2-bound crystal structure of 11 (red). D. Overlay of the β-hairpin 
selected for 12 by NAMFIS (grey), and the MDM2-bound crystal structure of 11 (red). 
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bound complex.10,13,15,95 Thus, the binding to a relatively flat surface, such as a PPI 
binding site, might require sufficient flexibility in order to allow the necessary 
geometrical adjustments. Stabilizing the bioactive conformation of macrocyclic 
peptides was previously shown to have either favorable or unfavorable entropic 
consequences.136,139 
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 8. Conformational analysis of CD36 modulating  
cyclic azapeptides (Paper V) 
 
8.1 The cluster of differentiation 36 receptor 
The cluster of differentiation 36 (CD36) receptor is a multiligand transmembrane 
receptor involved in a number of biological processes, for example atherosclerotic 
lesion formation,140 fatty acid signal transduction141 and angiogenesis.142 Due to the 
large range of ligands that bind to the CD36 receptor,143 including oxidized low 
density lipoprotein (oxLDL),140 malaria infected erythrocytes,144 long-chain fatty 
acids,141 hexarelin,145 and thrombospondins,142 CD36 is a drug target for several 
diseases. For instance, binding of oxLDL is one of the initial steps of foam cell 
formation leading to atherosclerosis.140 CD36 has multiple ligand binding 
domains140 and, for example, oxLDL and thrombospodin-1 bind at different 
sites.146 There are only a few crystal structures of CD36 complexes, and for many 
of its ligands the binding event is not characterized. 
 
8.2 Growth hormone releasing peptides 
Growth hormone releasing peptides (GHRPs) are synthetic hexa- or heptapeptides 
that are known to stimulate growth hormone release by binding the growth 
hormone secretagogue receptor 1a (GHS-R1a). The synthetic hexapeptide GHRP-
6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, Figure 26) was the first GHRP to be 
discovered.147 The 2-metyl-tryptophan analogue of GHRP-6, hexarelin ([2-Me-
W2]GHRP-6, Figure 26),145 was later shown to also bind to the CD36 receptor and  
 
 
Figure 26. The growth hormone releasing peptides GHRP-6 and hexarelin. 
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thereby provide cardiovascular protective effects, likely due to inhibition of 
oxLDL.143 The bioactive conformation of GHRP-6 analogues has been suggested 
to adopt a turn motif.148,149 
 
8.3 Azapeptides 
Azapeptides are peptides with at least one of the amino acid residues substituted 
for a semicarbazide, in other words one of the α-carbons is replaced with an α-
nitrogen (Figure 27). There are several examples of bioactive azapeptide 
analogues,150,151 including the marketed HIV-1 protease inhibitor atazanavir.152 The 
aza-moiety has typically been incorporated to induce conformational constrains151 
or to increase metabolic stability.153 The conformational behavior of azapeptides 
have been studied mostly using small linear peptides, and it has been shown that 
the aza-moiety can induce β-turns,74,154 and that the carbonyl–aza-amine (CO–NR) 
bond can display hindered single bond rotation.155 However, the solution 
conformations of azapeptides have in most cases not been described. 
 
 
Figure 27. General structures of the semicarbazide moiety and the azapeptide, with a 
semicarbazide incorporated at one of the amino acid residues (R2). 
 
8.4 Conformational preferences of macrocyclic azapeptide 
inhibitors of CD36 in aqueous solution (Paper V) 
Linear azapeptide analogues of GHRP-6 have previously been shown to modulate 
CD36 activity.156-159 As compared to GHRP-6 and hexarelin, the azapeptide 
analogue [Aza-Phe4]-GHRP-6 (His-D-Trp-Ala-aza-Phe-D-Phe-Lys-NH2) showed an 
increased CD36 versus GHS-R1a selectivity, while maintaining a comparable 
potency for CD36. CD and NMR measurements of this peptide revealed that the 
aza-moiety induced a β-turn.156,157 Alanine scans of the linear azapeptide analogues 
of GHRP-6 revealed that the D-Trp2 residue was important for CD36 inhibitory 
activity, whereas the His1 residue was not.158 Macrocyclic azapeptide analogues of 
 
GHRP-6 (15–17, Figure 28) were shown to modulate CD36 activity and 15 has the 
highest potency reported for a GHRP-analogue.159 
 
 
 
Figure 28. The investigated cyclic azapeptides and their respective IC50-values for CD36. 
 
As mentioned above, little is known about the binding event of CD36 and its 
ligands. In the case of GHRP-6 analogues, hexarelin has been shown to bind to a 
lysine-rich domain of CD36, which overlaps with the oxLDL binding site. 
Although aza-GHRP-6 analogues have been suggested to adopt β-turns, no crystal 
structure for any of the reported ligands in complex with CD36 is avaiable, and the 
bioactive conformation and the solution ensembles of these peptides have not yet 
been studied. Following the presumption that the protein-bound conformation of a 
flexible ligand is represented in its solution ensemble,21,160,161 the conformations of 
the macrocyclic azapeptides 15–17, in aqueous solution were investigated using the 
NAMFIS methodology. 
 
8.4.1 Results and discussion Paper V 
Due to conformational dynamics of the positions near the 3’ amine of azapeptides 
15–17, the 1H NMR assignment of these peptides was challenging. The TOCSY-
NOESY backbone walk, as described above, was used in combination with COSY, 
HSQC and HMBC spectra for the 1H NMR assignment. Compounds 16 and 17 
had broader peaks and fewer NOESY correlations than 15, suggesting higher 
flexibility. NOE-based distances and MCMM calculated theoretical ensembles of 
15–17 were derived as described above. NAMFIS analysis (Table 6) verified the line 
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 broadening-based assumption that 16 and 17 are more flexible than 15, with the 
overlaid solution ensembles of these compounds being shown in Figure 29. The 
ensemble of 16 was identified to contain 9 conformers, as compared to 6 for 15 and 
17, and was therefore concluded to be the most flexible of the three. The ensemble 
of 17 is more diverse than that of 15 (RMSD = 1.90 and 1.78, respectively). Thus, 
the flexibility order was found to be 16 > 17 > 15, which is opposite to the CD36 
activity order 15 > 17 > 16.159 
 
Table 6. Results of the NAMFIS analyses for the azapeptides 15–17 in D2O. 
15 16 17 
Conf. 
no.a 
% in 
ensembleb 
Conf. 
familyc 
Conf. 
no.a 
% in 
ensembleb 
Conf. 
familyc 
Conf. 
no.a 
% in 
ensembleb 
Conf. 
familyc 
1 3 A 7 2 A 16 22 A 
2 28 A 8 7 C 17 8 B 
3 11 B 9 11 C 18 22 - 
4 8 B 10 2 D 19 8 - 
5 11 B 11 3 C 20 16 - 
6 36 B 12 25 - 21 21 D 
   13 8 B    
   14 6 -    
   15 33 B    
aThe overlaid structures of the most populated conformations are shown in Figure 29. 
bPopulation of the indicated conformer in solution as selected by NAMFIS analysis, all other 
molar fractions are 1% or less. cThe conformational families are shown in Figure 30. RMSD 
overlaying backbone atoms: A = 0.91, B = 1.36, C = 0.53, D = 1.22. 
 
 
Figure 29. Overlaid backbone conformations (superpositioning α-carbons of Trp-Ala-Trp-Phe) 
of the solution ensembles of peptides 15–17. RMSD overlaying backbone atoms: 1 = 1.78, 2 = 
2.70, 3 = 1.90. Amino acid side chains are omitted for clarity. 
 
The conformations of the solutions ensembles of 15–17 were assigned to 
conformational families A–D (Table 6 and Figure 30) according to similarities in 
backbone geometry. Peptide 15 possesses two major conformations, A and B, 
supporting the previous results suggesting this to be more rigid than 16 and 17, 
whose solution conformations were distributed in a larger number of families. 
Conformational family A was populated to 31% for 15, 22% for 17, and 2% for 16, 
and thus follow the trend of the CD36 potency (15 > 17 > 16). Previous studies of 
linear azapeptide analogues of GHRP-6 have suggested that the aza-moiety may 
induce a β-turn.156,157 Such a turn was not found for any of the conformations 
among the conformations identified to exist in solution by the NAMFIS analysis. 
Instead, the conformations in family A displayed a type II’ β-turn for residues Ala-
D-Trp. As the only difference in the structure of peptides 15–17 is the side chain 
attached to the aza-nitrogen, this side chain is expected to cause the flexibility 
difference of the peptides. Stabilizing side chain-to-macrocycle hydrogen bonds 
were not found for the family A conformations. However, they were found for 
families B and D, with a higher population for peptide 17 as compared to 15, which 
might explain their difference in flexibility.  
 
 
Figure 30. Overlapped backbone conformations of the conformational families A–D of 
azapeptides 15–17 given in Table 6. Amino acid side chains are omitted for clarity. RMSD 
overlaying backbone atoms: A = 0.91, B = 1.36, C = 0.53, D = 1.22. Pink/purple conformations 
represent peptide 15, green conformations peptide 16, and blue conformations peptide 17. 
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 Previous studies of small linear azapeptides showed that the E-configuration along 
with hindered single bond rotation of the CO-NMe moiety is preferred when one 
of the aza-nitrogens is methylated, which might also constrain the peptide.155 
 
8.4.2 Summary Paper V 
Three macrocyclic azapeptides with activity for the CD36 receptor were 
investigated by NAMFIS. A decreased flexibility and increased solution population 
of conformational family A was shown to be beneficial for their CD36 inhibitory 
activity, that is 31% population of A for 15 (IC50 0.08 μM), 22% population of A 
for 17 (IC50 0.49 μM) and 2% population of A for 16 (no measurable activity). 
  
 
9. The solution conformations of roxithromycin 
adapting to the environment 
 
9.1 Cell permeability of macrocycles 
Macrocyclization is commonly used to improve cell permeability. Increased cellular 
penetration upon cyclization might be due to a decreased flexibility and decreased 
polarity as a result of formation of intramolecular hydrogen bonds and/or 
conformational shielding of polar functionalities.13,14 Although many macrocycles 
are administrated orally, they generally belong to the bRo5 ligands, and often have 
both low cellular penetration and low oral bioavailability. However, the analysis of 
the properties of orally bioavailable drugs in the bRo5-space has shown that, as 
compared to the Lipinski rules,3,14 the molecular weight of these compounds may 
be increased up to 1000 Da, the PSA to 250 Å2 and the number of HBAs to 15.11,14 
For the analysis of macrocyclic peptide conformational preferences in relation to 
permeability, solution NMR spectroscopy has previously been used, with CDCl3 
mimicking the cell membrane and D2O mimicking the cell surroundings.162 
 
9.2 Roxithromycin 
Roxithromycin (Figure 31) is a macrocyclic antibacterial agent based on the 
structure of erythromycin (Figure 31), where replacement of the 9-keto group by 
the 9-[O-(2,5-dioxahexyl)oxime] side chain results in increased metabolic stability 
and better oral bioavailability.163 It has been shown using parallel artificial 
membrane permeability assay (PAMPA) that passive diffusion is higher for 
roxithromycin than for erythromycin, which might partly explain its higher 
bioavailability.164 Roxithromycin and erythromycin belong to the group of 
macrolides, in other words natural products with a macrocyclic lactone ring of at 
least 12 atoms. Their antibacterial activity is the result of binding to the bacterial 
ribosome and thereby inhibit protein biosynthesis.165 The solution ensemble of 
roxithromycin has been proposed to contain one major conformation, which is 
highly similar to the crystal structure,166 and some minor conformations that could 
not be identified experimentally due to their low solution populations, in both 
hydrophilic and hydrophobic solvents.167-169 The major solution conformation has 
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Figure 31. The structures of macrolides roxithromycin and erythromycin. 
 
the oxime chain folded over, and hydrogen bonded to, the macrocycle. However, 
dependence of the solution conformation ensemble of roxithromycin on its 
environment has not yet been described in detail. As a part of a project examining 
the ability of computational techniques to predict the cell permeability of 
macrocycles, the conformational preferences of roxithromycin were studied by 
solution NMR spectroscopy in CDCl3, mimicking the cell membrane, and in D2O, 
mimicking the cell surroundings. 
 
9.3 Solvent dependence of the conformations of roxithromycin  
The proton assignments of roxithromycin in CDCl3 and D2O (Appendix IX) were 
derived from TOCSY, NOESY, COSY, and HSQC spectra. Interproton distances 
(Appendix X) were calculated from NOE build-ups as described above. The 
NOESY spectrum showed the same phase of the diagonal peaks and cross peaks 
for roxithromycin in D2O and the opposite phase for roxithromycin in CDCl3, 
indicating that roxithromycin interacts more with the solvent in D2O. Solution 
conformations were derived by NAMFIS analysis using an input ensemble 
containing conformers generated by MCMM searches in chloroform and water 
using the OPLS and Amber* force fields (Appendix XI). Conformers from all 
individual MCMM searches were combined, and following redundant conformer 
elimination, comparing heavy atoms, generated the input ensemble for NAMFIS 
analysis (Appendix XI). The same input ensemble was used for analysis of the data 
from CDCl3 and from D2O. In the experimental input only data from the 
macrocycle, and not the flexible oxime chain or the sugars, were used. The initial 
 
NAMFIS was run with the MCMM generated ensemble. In the following run the 
crystal structures of roxithromycin166,170,171 were added to the input ensemble for 
comparison (Table 7). 
 
The ensemble of roxithromycin in CDCl3 selected by NAMFIS from the MCMM 
ensemble (Table 7) contains three highly similar conformations (Figure 32 A). In 
line with previous reports on the solution conformation of roxithromycin,167-169 the 
oxime chain was found to be oriented above the macrocycle. When the crystal 
structures were added to the ensemble, one of them (Figure 32 B)170 was selected to 
100% (Table 7). Adding the crystal structure to the ensemble allowed the correct 
positioning of the oxime chain and also revealed that the oxime chain is hydrogen 
bonded to C(6)-OH. As shown by the overlaid conformations in Figure 32 C, the 
crystal structure and the major conformation from the initial run are highly similar. 
In conclusion, in chloroform, which was used to mimic the cell membrane, the 
oxime chain is fully folded over the macrocycle as shown in Figure 32 B. NAMFIS 
was able to capture the side chain orientation even when only data considering the 
macrocycle, and not the oxime chain, were used as input. 
 
Table 7. Conformational populations derived by NAMFIS analysis for roxithromycin in CDCl3 
and D2O solutions. 
MCMM ensemblea MCMM ensemble + X-Ray structuresa 
CDCl3 D2Oe CDCl3 D2Oe 
Conf. No.b %c Conf. No.b 
No. 
%c Conf. No.b %c Conf. No.b %c 
1 17 2 14 X-rayd  100 4 47 
2 12 4 59   5 10 
3 71 5 7   6 19 
  6 6   9 3 
  7 4   10 14 
  8 8   X-rayd  6 
aSee Appendix XI. bConformations in italic have the oxime chain-to-macrocycle hydrogen 
bonding. cPopulation of the indicated conformer in solution, as deduced by NAMFIS analysis, all 
other molar fractions are 1% or less. dCSD: KAHWAT. eConformations 2 and 10, 7 and X-ray, 6 
and 8, and 9 and 4 are highly similar. 
However, although the MCMM conformational search did sample conformations 
with the oxime chain folded over the macrocycle, it did not sample hydrogen 
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individual MCMM searches were combined, and following redundant conformer 
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NAMFIS was run with the MCMM generated ensemble. In the following run the 
crystal structures of roxithromycin166,170,171 were added to the input ensemble for 
comparison (Table 7). 
 
The ensemble of roxithromycin in CDCl3 selected by NAMFIS from the MCMM 
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line with previous reports on the solution conformation of roxithromycin,167-169 the 
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was able to capture the side chain orientation even when only data considering the 
macrocycle, and not the oxime chain, were used as input. 
 
Table 7. Conformational populations derived by NAMFIS analysis for roxithromycin in CDCl3 
and D2O solutions. 
MCMM ensemblea MCMM ensemble + X-Ray structuresa 
CDCl3 D2Oe CDCl3 D2Oe 
Conf. No.b %c Conf. No.b 
No. 
%c Conf. No.b %c Conf. No.b %c 
1 17 2 14 X-rayd  100 4 47 
2 12 4 59   5 10 
3 71 5 7   6 19 
  6 6   9 3 
  7 4   10 14 
  8 8   X-rayd  6 
aSee Appendix XI. bConformations in italic have the oxime chain-to-macrocycle hydrogen 
bonding. cPopulation of the indicated conformer in solution, as deduced by NAMFIS analysis, all 
other molar fractions are 1% or less. dCSD: KAHWAT. eConformations 2 and 10, 7 and X-ray, 6 
and 8, and 9 and 4 are highly similar. 
However, although the MCMM conformational search did sample conformations 
with the oxime chain folded over the macrocycle, it did not sample hydrogen 
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 bonding to C(6)-OH, but only to C(11)-OH. It is well known that MCMM does 
not describe the orientation of flexible side chains as well as backbone geometry.52 
 
  
Figure 32. A. The conformations of roxithromycin obtained in the NAMFIS analysis of the 
MCMM ensemble in CDCl3, with hydrogen bonding to C(11)-OH. Sugar residues are omitted for 
clarity. B. The crystal structure selected by NAMFIS from the ensemble containing the three 
crystal structures, with hydrogen bonding to C(6)-OH (CSD: KAHWAT).170 C. Overlay of the 
major conformation from A (blue) and the crystal structure in B (red), showing their similarity in 
macrocycle geometry and difference in oxime chain orientation. Sugar residues are omitted for 
clarity. 
 
The aqueous solution ensemble of roxithromycin was, in contrast to previous 
reports,167-169 shown to contain several conformers (Table 7). Importantly, the 
majority of these conformations (80%) did not have the oxime chain oriented over 
the macrocycle but solvent exposed. As illustrated by the overlaid conformations in 
Figure 33 A, the aqueous ensemble of roxithromycin shows a relatively diverse set 
of macrocycle geometries. Similar to the analyses of the CHCl3-data, adding the 
crystal structures to the ensemble did not change the outcome of the NAMFIS 
analysis of the D2O-data significantly. Hence, in both ensembles ~20% of the 
conformations have the oxime chain over the macrocycle. When the X-ray 
structures are added 6% of the conformers show hydrogen bonding of the oxime 
chain to C(6)-OH and the rest to C(11)-OH. The protein-bound conformation of a 
flexible ligand is expected to be represented in its solution ensemble,21,160,161 and 
accordingly the previously published protein bound geometry,172 identified by X-ray 
diffraction, was identified to be present in solution. This structure (Figure 33 B) is 
highly similar to conformation 10 (Figure 33 C), which has a solution population of 
14%. The oxime chain is not folded over the macrocycle in the bioactive 
conformation in which the C(6)-OH, C(11)-OH and C(12)-OH form hydrogen 
bonds to the ribosome.172 It should be noted that the major conformation in CDCl3 
 
does not show as high similarity to the bioactive conformation, as it has previously 
been proposed.165 Overall, it has been shown that in CDCl3 the oxime chain of 
roxithromycin is oriented over the macrocycle, with this conformation being 
dominant in this solvent. In contrast, the solution ensemble of roxithromycin in 
D2O consists of six different conformers, and the oxime chain is oriented over the 
macrocycle only in ~20% of the ensemble. Thus, these data reveal that the 
structure of roxithromycin converts from a more open conformation in polar 
media to a more closed and less flexible in non-polar media. Formation of 
intramolecular hydrogen bonds, as well as reduction of PSA, has been shown to 
internalize polarity and improve cell permeability and oral bioavailability for bRo5-
macrocycles.11,12 For the roxithromycin ensembles, 66% have macrocycle 
intramolecular hydrogen bonds in CDCl3 as compared to 60% in D2O, and the 
PSA weighted to the molar fractions of the conformers in the two solvents is 169 
Å2 and 173 Å2, respectively. Although these differences are small, together with the 
overall flexibility of roxithromycin they might contribute to an improved passive 
diffusion as compared to erythromycin. It has previously been suggested that 
conformational flexibility may be beneficial for permeability by allowing the 
molecule to adapt to the transitional environment at the water-lipid interface at the 
boundary of the cell membrane.162 
 
 
 
Figure 33. A. The solution conformational ensemble of roxithromycin in D2O as derived by 
NAMFIS analysis using an ensemble generated by MCMM and including its crystal structures. 
Sugars are omitted for clarity. B. The X-ray structure of roxithromycin bound to the 50S subunit 
of the eubacterium Deinococcus radiodurans (PDB: 1JZZ).172 C. Overlay of B and conformation 10, 
showing their resemblance. The cladinose sugars are omitted for clarity. 
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clarity. B. The crystal structure selected by NAMFIS from the ensemble containing the three 
crystal structures, with hydrogen bonding to C(6)-OH (CSD: KAHWAT).170 C. Overlay of the 
major conformation from A (blue) and the crystal structure in B (red), showing their similarity in 
macrocycle geometry and difference in oxime chain orientation. Sugar residues are omitted for 
clarity. 
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 10. Concluding remarks 
This thesis describes the solution conformational ensembles of various 
macrocycles. Weak interstrand interactions were demonstrated to provide 
significant stabilization of the β-hairpin conformation. In this respect a halogen 
bond appears to be just as powerful for conformation direction as a hydrogen 
bond. Further, the flexibility of bioactive cyclic peptides in relation to their potency 
was studied and the importance of a balanced flexibility/rigidity for bioactivity was 
demonstrated. Whereas for one macrocycle rigidification in a presumptive bioactive 
conformation may provide increased bioactivity, for another it may result in 
decreased potency. The conformational preference of a macrolide antibiotic in 
different environments was also examined. Its structure was shown to convert 
from a more open conformation in a hydrophilic environment to a more closed 
and less flexible in a hydrophobic environment, proposing this to be the cell-
permeable conformation. The information gained in these investigations could 
provide valuable insight in the process of drug design. 
 
Further investigations of special interest include optimization of the cyclic β-hairpin 
model system used for investigation of weak interactions. More specifically, we 
would like to design peptides with bromine and iodine halogen bond donor sites. 
In addition, we wish to perform further variable temperature NMR studies, 
preferably in different solvents. Other studies of interest include the evaluation of 
the conformation and dynamics of erythromycin and other macrolides, using 
NAMFIS, to gain further insights into their conformational preferences in relation 
to permeability. Likewise, we would like to continue the conformational evaluation 
of additional cyclic azapeptides to establish their conformational preferences in 
correlation to their bioactivity. 
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Appendix V. The input ensemble for the Ala(Cl)3 and Ser(Me)8 side chain 
NAMFIS analysis of peptide 9. 
 
 
 
 
Figure A1. The input ensemble for the NAMFIS analysis of peptide 9, with the Ala(Cl)3 and 
Ser(Me)8 interactions as constrains. The ensemble was generated by rotating the Cα—Cβ bond, 
as indicated by the arrows in the schematic β-hairpin in the square. 
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 Appendix VI. Synthesis of 11. 
 
 
 
 
Appendix VI. Synthesis of 11.
 
 
 
 
 
Appendix VII. Synthesis of 12 and 13. 
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Appendix VII. Synthesis of 12 and 13. 
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 Appendix VIII. Synthesis of 14. 
 
 
 
 
 
Appendix IX. 1H NMR assignment for Roxithromycin. 
Proton assignments were derived from TOCSY, NOESY, COSY, and HSQC 
NMR spectra recorded at 25 °C on a 900 MHz BRUKER Avance III HD NMR 
spectrometer equipped with a TCI cryoprobe. 
 
Table A1. 1HNMR assignment (ppm) of roxithromycin in CDCl3 and D2O. 
 
Macrocycle 
 
Sugars 
CDCl3 D2O CDCl3 D2O 
1 - - 1' 4.43 4.6 
2 2.9 3.06 2' 3.49 3.53 
2-Me 1.18 1.23 2'-OH 3.28 - 
3 3.98 3.84 3' 2.49 3.48 
4 2.03 2.02 3'-NMe2 - 2.86 
4-Me 1.09 1.07 4' 1.70, 1.27 2.12, 1.57 
5 3.54 3.53 5' 3.5 3.89 
6 - - 5'-Me 1.23 1.31 
6-Me 1.49 1.44 1'' 4.84 4.95 
7 2.35, 1.58 1.67, 4.56 2'' 2.36, 1.56 2.53, 1.68 
8 3.75 3.74 3''-Me 1.24 1.25 
8-Me 1.03 1.14 3''-OMe 3.31 3.32 
9 - - 4'' 3.02 3.23 
10 2.67 2.94 4''-OH 2.21 
 10-Me 1.19 1.19 5'' 4 4.13 
11 3.82 3.68 5''-Me 1.28 1.31 
11-OH 4.31 - 
   12 - - 
   12-Me 1.14 1.23 
   12-OH 3.14 - 
   13 5.1 5.14 
   14 1.92, 1.47 1.87, 1.55 
   15 0.85 0.85 
   16 5.19, 5.17 5.22, 5.19 
   17 3.80, 3.72 3.84 
   18 3.57, 3.56 3.64 
   19 3.42 3.4 
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 Appendix X. Interproton distances for Roxithromycin. 
NOE build-ups were recorded without solvent suppression with mixing times of 
100, 200, 300, 400, 500, 600, and 700 ms. The relaxation delay was set to 2.5 s, and 
16 scans were recorded with 16384 data points in the direct dimension and 512 
data points in the indirect dimension. Distances were calculated using geminal 
methylene protons (1.78 Å) as reference. The NOE peak intensities were calculated 
according to ([cross peak1 × cross peak2]/[diagonal peak1 × diagonal peak2])0.5. At 
least 4 mixing times giving a linear (R2 > 0.97) initial build-up rate (σij) were used. 
The interproton distances (rij) were calculated according to the equation 
rij=rref(σref/σij)(1/6). 
 
Table A2. Interproton distances (Å) for roxithromycin derived from NOE build-up 
measurements in CDCl3. 
No. Proton A Proton B σ R2 Distance rAB (Å) 
1 13 11 0.0000091 0.99 2.31 
2 3 5 0.0000250 0.99 1.95 
3 11 4 0.0000013 0.99 3.19 
4 2 4 0.0000110 0.99 2.24 
5 3 4 0.0000130 0.99 2.18 
6 11 10 0.0000147 0.99 2.13 
7 10 7B 0.0000049 0.99 2.61 
8 8 6Me 0.0000357 0.98 1.84 
9 2 4Me 0.0000314 0.99 1.88 
10 10 8Me 0.0000335 0.99 1.86 
11 10 12Me 0.0000475 0.99 1.75 
12 5 4Me 0.0000021 0.98 2.94 
13 5 6Me 0.0000257 0.98 1.94 
14 1'' 2''A 0.0000068 0.99 2.43 
15 1'' 2Me 0.0000435 0.99 1.78 
16 1'' 3 0.0000310 0.99 1.88 
17 1' 5' 0.0000272 0.98 1.92 
18 1' 3' 0.0000464 0.99 1.76 
19 4'' 5''Me 0.0000235 0.99 1.97 
20 1' 4Me 0.0000138 0.99 2.15 
21 5 5'' 0.0000071 0.99 2.41 
22 11 12Me 0.0000075 0.97 2.44 
ref. 2''A 2''B 0.0000433 
 
0.99 1.78 
ref. 17A 17B 0.0000380 
 
0.76 1.76 
 
 
Table A3. Interproton distances (Å) for roxithromycin derived from NOE build-up 
measurements in D2O. 
No. Proton A Proton B σ R2 Distance rAB (Å) 
1 13 11 0.0000193 0.99 2.93 
2 11 4 0.0000623 0.99 2.41 
3 2 4 0.0000314 0.99 2.70 
4 10 4 0.0000035 0.98 3.90 
5 3 5 0.0000235 0.99 2.84 
6 5 4 0.0000110 0.99 3.22 
7 3 2 0.0000084 0.99 3.37 
8 3 4 0.0000167 0.99 3.00 
9 11 10 0.0000426 0.99 2.57 
10 13 12Me 0.0000036 0.98 3.89 
11 3 2Me 0.0000060 0.99 3.56 
12 10 8Me 0.0000073 0.99 3.45 
13 10 12Me 0.0000243 0.99 2.82 
14 2 4Me 0.0000131 0.98 3.13 
15 5 6Me 0.0000228 0.98 2.85 
16 3 6Me 0.0000038 0.98 3.85 
17 3 4Me 0.0000018 0.99 4.35 
18 10 8Me 0.0000364 0.98 2.64 
19 4 6Me 0.0000029 0.98 4.02 
20 1'' 2 0.0000018 0.98 4.35 
21 1' 4Me 0.0000185 0.99 2.95 
22 1' 5'' 0.0000660 0.99 2.39 
23 1' 3''Me 0.0000080 0.99 3.40 
24 1' 6Me 0.0000028 0.98 4.04 
ref. 2''A 2''B 0.0003853 0.99 1.78 
ref. 4'A 4'B 0.0004024 0.98 1.77 
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 Appendix XI. MCMM conformational search of Roxithromycin. 
The conformational searches were performed using the Monte Carlo algorithm 
with intermediate torsion sampling, 50 000 Monte Carlo steps, and a RMSD cut-off 
set to 2.0 Å, followed by molecular mechanics energy minimization with the 
software Macromodel (v.9.1) as implemented in the Schrödinger package. The 
energy minimization was performed using the Polak-Ribiere type conjugate 
gradient (PRCG) with maximum iteration steps set to 5000. All conformations 
within 42 kJ/mol from the global minimum were saved. The results of the four 
independent searches performed using OPLS-2005 or Amber* as force field, and 
with CHCl3 and H2O as solvation model, are given below. The ensembles from the 
conformational searches were combined, and elimination of redundant 
conformations by comparisons of the heavy atom coordinates applying the RMSD 
cutoff 1-1.5 Å was performed. These ensembles were combined and redundant 
conformations were eliminated again, giving the ensemble used for NAMFIS 
analysis. To this ensemble the three available crystal structures of roxithromycin 
were added (CSD: FUXYOM,166 EWETUV171 and KAHWAT170). 
 
Table A4. Results of the MCMM conformational analysis. 
  Number of conformations 
  Totala 
Within 12.6 
kJ/molb 
Following redundant 
conformer eliminationc 
CHCl3 OPLS 177 13 62  Amber* 197 25 
H2O OPLS 172 14 38 
 
Amber* 127 14 
aTotal number of unique conformations found. The global minimum was found for all 
investigated compounds at least 30 times. bConformations found within 12.6 kJ/mol (3.0 
kcal/mol) of the global minimum. cConformations obtained after redundant conformation 
elimination with the RMSD cutoff 1.5 Å (CHCl3) and 1.Å (H2O) for heavy atoms. These 
ensembles were again combined and reduced by redundant conformer elimination (RMSD cutoff 
= 1.5 Å) giving the ensemble used as input in the NAMFIS analysis (66 conformers). 
  
 
Appendix XII. NAMFIS analysis of Roxithromycin. 
Solution ensembles were determined by fitting the experimentally measured 
distances to those back-calculated for computationally predicted conformations 
following previously described protocols. CH2 signals were treated according to the 
equation d=(((d1-6)+(d2-6))/2)-1/6, and methyl signals according to d=(((d1-6)+(d2-
6)+(d3-6))/3)-1/6. The NAMFIS ensemble analyses were validated using standard 
methods, that is through evaluation of the reliability of the conformational 
restraints by the addition of 10% random noise to the experimental data, by the 
random removal of individual restraints, and by comparison of the experimentally 
observed and back-calculated distances. Since the orientations of flexible parts of 
molecules are not as well predicted by the conformational searches as the more 
rigid parts, only macrocycle interactions were included in the initial NAMFIS 
analyses, corresponding to distance 1-13 for CDCl3 and distance 1-19 for D2O 
(Table A2 and A3). 
 
Table A5. Experimentally determined and back-calculated (NAMFIS) interproton distances (Å). 
MCMM  
CDCl3 
MCMM + X-ray 
CDCl3 
MCMM 
D2O 
MCMM + X-ray 
D2O 
Exp. Calc. Exp. Calc. Exp. Calc. Exp. Calc. 
2.31 2.80 2.31 2.79 2.93 2.90 2.93 2.85 
1.95 2.57 1.95 2.58 2.41 2.82 2.41 2.87 
3.19 3.67 3.19 2.50 2.70 2.44 2.70 2.39 
2.24 2.63 2.24 2.54 3.90 4.00 3.90 3.80 
2.18 2.53 2.18 2.35 2.84 2.32 2.84 2.30 
2.13 2.68 2.13 2.56 3.22 2.91 3.22 2.96 
2.61 2.94 2.61 2.42 3.37 2.90 3.37 2.73 
1.84 2.59 1.84 2.57 3.00 2.62 3.00 2.66 
1.88 2.57 1.88 2.48 2.57 2.68 2.57 2.69 
1.86 2.70 1.86 2.64 3.89 2.96 3.89 3.07 
1.75 2.72 1.75 2.52 3.56 3.26 3.56 3.31 
2.94 3.14 2.94 3.63 3.45 3.55 3.45 3.38 
1.94 2.66 1.94 2.72 2.82 2.74 2.82 2.78 
    3.13 2.70 3.13 2.78 
    2.85 2.81 2.85 2.83 
    3.85 3.93 3.85 3.90 
    4.35 3.90 4.35 3.88 
    2.64 2.97 2.64 2.86 
    4.02 2.58 4.02 2.62 
RMS=0.61 RMS=0.60 RMS=0.49 RMS=0.48 
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